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1. Introduction
1.1 The c-Myc transcription factor
c-myc was identified as the cellular 
homolog of the oncogene v-myc of the avian 
myelocytomatosis virus (Vennstrom et al., 
1982).  The avian retrovirus MC29 induces 
a wide spectrum of neoplastic diseases 
in chickens, including renal and hepatic 
carcinomas, sarcomas, and leukemias (Graf 
et al., 1978).  It was subsequently found 
that the c-myc proto-oncogene is activated 
in various animal and human tumors (Cole 
et al., 1986).  Only in the USA, c-myc 
deregulation is involved in 70,000 cases of 
human cancer each year that result in death 
(Dang, 1999; Nesbit et al., 1999).  For this 
reason, efforts to study this proto-oncogene 
and understanding its function have been 
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and noncanonical: 5’-CANNTG-3’), whereas 
the HLH-LZ domain is required for protein 
binding to Max.  The N-terminal domain 
(NTD) harbors two highly conserved ‘Myc 
boxes’ I and II (MBI and MBII), essential 
for transactivation of c-Myc target genes 
(Dang, 1999; Pelengaris et al., 2002).  MBII 
is critical for the majority of c-Myc functions 
(Oster et al., 2002). In the central region, 
we find the conserved Myc boxes III and 
IV, and nuclear localization signals 1 and 2 
(NLS1 and NLS2) (Figure I1b).  In addition, 
the central region of the Myc protein has a 
highly acidic stretch containing multiple CKII 
phosphorylation sites important for its activity 
(Dang et al., 1988; Henriksson et al., 1993).
1.3 Controlling c-Myc
c-Myc nuclear protein is expressed 
ubiquitously during embryogenesis and in 
those adult tissue compartments with high 
proliferative capacity.  Resting or terminally 
differentiated cells have nearly undetectable 
c-Myc mRNA and protein levels, but 
expression is activated rapidly following 
exposure to a variety of mitogens, and 
promotes G0/G1 transition (Campisi et al., 
1984; Kelly et al., 1983; Eilers, 1991).  c-Myc 
activity is normally controlled precisely by 
external signals including growth factors, 
mitogens and β-catenin, which promote 
proliferation, and factors such as TGF-β, which 
inhibit it.  c-Myc is also a target gene of the 
c-Myb transcription factor.  In dividing cells, 
significant in recent years, with the hope 
that therapeutic insights will emerge.
c-Myc belongs to the myc family 
of basic helix-loop-helix leucine zipper 
(bHLH-LZ) transcription factors, together 
with N-Myc, L-Myc, B-Myc and s-Myc; 
however, only cMyc, L-Myc, and N-Myc 
have neoplastic potential (Henriksson et 
al., 1993).  N-myc and lmyc were also 
identified by their homology with v-myc 
in amplified sequences of neuroblastoma 
and lung small cell tumors, respectively 
(Kohl et al., 1986; Nau et al., 1986).
1.2 The c-Myc protein
The c-myc gene, located on human 
chromosome 8, is comprised by 3 exons 
and has four different promoters.  The 
c-myc gene encodes a 64 kDa protein 
if starting at the canonical AUG start 
codon in exon 2, or a 67 kDa polypeptide 
if initiated 15 codons upstream of this 
AUG, in exon 1 (Figure I1a).  There are no 
clear functional differences between them 
(Hann et al., 1984; Spotts et al., 1990).
The c-Myc protein has several 
functional domains.  The C-terminal 
domain (CTD) harbors the basic helix-
loop-helix leucine zipper (bHLH-LZ) motif 
for dimerization with its partner, Max, and 
subsequent DNA binding of Myc-Max 
heterodimers.  The basic region is necessary 
to bind to DNA consensus sequences, 
called E-boxes (canonical : 5’-CACGTG-3’, 
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c-Myc levels are maintained at a relatively 
constant intermediate level throughout 
the cell cycle (Pelengaris et al., 2002).
Once c-Myc is activated, its half life 
is very short (20-30 minutes) (Hann et al., 
1984), and its degradation is mediated by the 
ubiquitin/26S proteasome pathway (Gross-
Mesilaty et al., 1998).  Phosphorylation 
of c-Myc is also involved in the stability of 
the protein.  Although there are at least ten 
major phosphorylation sites in the protein 
(Henriksson et al., 1993), two are mainly 
responsible for c-Myc stabilization and 
degradation: Ser62 (S62) and Thr58 (T58). 
Phosphorylation of S62 stabilizes c-Myc 
protein, whereas phosporylation on T58 
leads to degradation (Hann, 2006).  Point 
mutation of these residues results in c-Myc 
transformation activity (Nasi et al., 2001).
1.4 Myc/Max/Mad network
The search for a Myc binding partner 
protein resulted in the discovery of an HLH-
LZ human Max protein (Blackwood et al., 
1991).  Myc interacts specifically in vivo 
with a nuclear protein called Max, to form 
a complex with sequence-specific DNA-
binding activity (Blackwood et al., 1992).
Max also has a bHLZ-LZ region, 
and disruption of the HLH-LZ structure 
prevents its association with Myc.  Several 
forms of Max protein have been described, 
presumably derived from alternative splicing. 
The 22 kDa form (p22Max) differs from the 
21 kDa form (p21Max) by the insertion of 
nine amino acids upstream of the basic 
region.  Both are the major Max protein 
forms detected in a wide variety of cell 
types and species, and both heterodimerize 
with Myc (Blackwood et al., 1992).
In vitro-translated Myc-Max complexes 
appear to bind to E-boxes with a higher 
affinity than does either homodimer alone. 
The E-box sequence is sensitive to CpG 
methylation (Prendergast et al., 1991).  In 
contrast to tightly regulated Myc expression, 
Max levels are unaffected by changes in 
the cell cycle.  Both max mRNA and the 
encoded protein are readily detected in 
quiescent cells at levels comparable to those 
in a cycling cell.  Moreover, Max expression 
is not influenced by Myc levels, and it 
appears to be highly stable, with a half life 
of over 12 hours (Blackwood et al., 1992).
In vitro binding studies show that 
Max can form homodimers in addition 
to its ability to heterodimerize with Myc 
family proteins.  In quiescent cells, Max-
Max dimers are predominant; in mitogen-
activated cells, the presence of Myc causes 
a shift to Myc-Max heterodimers, because 
Max has higher affinity for Myc than for 
itself (Spencer et al., 1991).  Max/Max 
homodimers do not activate transcription 
of target genes, as they lack an activation 
domain (Kato et al., 1992); the activation 
activity of Myc-Max dimers is therefore due 
only to the c-Myc transactivation domain.
Other proteins in this network are the 
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Mad proteins.  Mad was discovered through 
its ability to bind Max (Hurlin et al., 1995).  The 
Mad protein family, including Mxi-1, Mad1, 
Mad3, Mad4, bear the Sind3-interacting 
domain motif, which recruits Sin3, N-Cor and 
other proteins with deacetylase activity, which 
is the main mode of transcriptional silencing 
by Mad.  The expression of different Mad/
Mxi-1 protein family members coincides with 
downregulation of c-Myc expression, and 
cells begin to exit the cell cycle.  Mad proteins 
are restricted to post-mitotic differentiated 
cells (Chin et al., 1995).  Mad/Max dimers 
act as transcriptional repressors and bind 
to the same consensus sequences as Myc/
Max, the E-boxes (Amati et al., 2001); there 
is thus a balance between Myc/Max and 
Mad/Max heterodimers that determines the 
switch between cell states and transcriptional 
activation or repression of their common 
target genes (Amati et al., 2001) (Figure I2a).
1.5 Mechanisms of c-Myc transcriptional 
activation
Myc/Max heterodimers bind the 
E-box sequences and c-Myc interacts 
with the TATAbinding protein (TBP) and 
the transcriptional machinery to regulate 
expression of their target genes.  The first 
level of DNA packaging in eukaryotes is its 
a. MYC/MAX/MAD activation of target genes expression
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wrapping around the core histones H2A, H2B, 
H3, and H4 to form the nucleosome (Luger et 
al., 1997).  The promoter regions would thus 
be inaccessible to transcription factors that 
modulate gene expression. Two different 
chromatin remodeling processes have been 
reported for c-Myc, histone acetylation and 
ATP-dependent remodeling of nucleosomes.
Acetylation levels are controlled by 
a variety of histone acetyltransferases 
(HAT) and deacetylases (HDAC), which are 
recruited to promoters by sequence-specific 
activators and repressors, and mediate 
their transcriptional activities (Kingston et 
al., 1999).  c-Myc recruits, and binds by 
its N-terminal transactivation domain, a 
coactivator multisubunit complex containing 
transformation/transcription domain-
associated protein (TRAPP) and HAT such 
as GNC5 (McMahon et al., 1998, 2000), 
important for modulating the acetylation 
status of core histones (Figure I3). 
Activation of a MycER chimera (Littlewood 
et al., 1995) in quiescent cells rapidly 
induced H4 acetylation.  In the second 
process, Myc/Max binds to a component 
of the SWI/SNF complex with ATPase 
activity involved in nucleosome remodeling 
(Park et al., 2001).  These two processes 
allow an open chromatin conformation and 
accessibility to RNA polymerase II (polII) 
to activate c-Myc target genes, translating 
mitogenic stimuli into chromatin modification.
1.6 Transcriptonal repression by c-Myc
Transcriptional repression mechanism 
by c-Myc is not as well understood as c-Myc 
dependent activation.  Most c-Myc-repressed 
genes show a TATA-less promoter with an 
Figure I3 
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Initiator element within (Inr), but c-Myc-
dependent repression was also reported in 
promoters lacking Inr (Gartel et al., 2003).  The 
Inr element is deﬁned as a weak consensus 
YYCAYYYYY, where Y is a pyrimidine base.
c-Myc represses transcription of its 
target genes by two distinct mechanisms. 
One is dependent on a transcriptional initiator 
(Inr) element in TATA-less promoters, and 
requires interaction with Ying Yang (YY1) 
and TFII-I activator proteins (Shrivastava 
et al., 1993; Roy et al., 1993); the other is 
via activity of Miz-1, a zinc-finger protein 
identified as a c-Myc partner (Staller et al., 
2001) (Figure I2b).  TFII-I binds and stimulates 
basal transcription from the Inr element (Roy 
et al., 1991) by sequential addition of other 
general factors, providing a mechanism for 
initiation of transcription from TATA-less 
promoters.  C-Myc can bind TFII-I and form 
a complex associated with DNA containing 
an Inr sequence, which resists further 
binding of basal transcriptional machinery, 
preventing transcriptional activation from the 
Inr (Roy et al., 1993).  The Inr-independent 
mechanism involves inhibition of Smad-
mediated activation of the Sp1 transcription 
factor by c-Myc (Feng et al., 2002).
1.7 c-Myc biological functions
 1.7.1 c-Myc and the cell cycle
c-Myc can promote cell cycle 
progression.  A rat fibroblast cell line in 
which both c-myc alleles were deleted 
shows very reduced proliferation rates and 
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deficiency in global mRNA and protein 
synthesis (Mateyak et al., 1997), whereas 
ectopic induction of Myc activity is sufficient 
to drive quiescent growth factor-deprived 
fibroblasts into the cell cycle (Eilers et al., 
1991).  This demonstrates that Myc regulates 
genes that mediate the mitogenic response.
Cell cycle progression is promoted by 
cyclin-dependent kinases (CDK) and their 
cyclin regulatory subunits, and is repressed 
by cell cycle inhibitors such as p27 or p21. 
c-Myc promotes G1-S transition through gene 
activation and repression; it activates cyclin 
A and D1, and also induces cyclin E-CDK2 
activity early in the G1 phase (Steiner et al., 
1995).  CCND2 and CDK4 are also direct 
c-Myc targets, and their expression leads to 
sequestration of the CDK inhibitor KIP1 (p27) 
in cyclin D2-CDK4 complexes (Bouchard 
et al., 1999).  This prevents p27 binding to 
cyclin E-CDK2 complexes.  Moreover, KIP1 
is degraded by two c Myc target genes, CUL-
1 and CKS (Hermeking et al., 2000).  Cyclin 
E-CDK2 complexes are now accessible to 
phosphorylation by cyclin activating kinase 
(CAK), resulting in increased activity of CDK2 
and CDK4, which in turn hyperphosphorylate 
Retinoblastoma protein (Rb) to allow its 
release from E2F (Figure I4).  cdc25 is also 
a direct target of c-Myc, which is responsible 
for CDK2 and CDK4 activation (Galaktionov 
et al., 1996).  c-Myc can repress other CDK 
inhibitors such as p15 and  p21, which 
mediate cell cycle arrest via Miz-1 and 
SP1 (Dang, 1999; Grandori et al., 2000).
1.7.2 The role of c-Myc in cell 
growth
c-Myc involvement in metabolism is 
further suggested by the roles of some of 
its target genes that encode translational 
regulatory factors, such as eIF-2α and eIF-
4E, as well as ECA39, which is implicated 
in amino acid transport, and RNA helicase 
MrDb, IRP-2 and Hferritin (Jones et al., 1996; 
Rosenwald et al., 1993; Grandori et al., 2000).
RNA polymerase III (polIII) is involved 
in the generation of transfer RNA and 5S 
ribosomal RNA is required for protein synthesis 
in growing cells.  PolIII is activated via cMyc 
binding to TFIIIB (Gomez-Roman et al., 2003).
If c-Myc activates metabolism and 
protein synthesis, it is plausible that it is 
also linked to cell growth, and studies of 
c-Myc function in cell size and body size 
demonstrate this implication.  In Drosophila 
melanogaster, downregulation of dmyc 
(c-myc ortholog) gives rise to smaller flies 
as a result of a decrease in cell size and 
number (Figure I5); dmyc overexpression 
yielded larger cells with a normal division 
rate (Johnston et al., 1999).  c-Myc is 
therefore an integrator of cell proliferation 
and metabolism.  Another example is the Eµ-
myc transgenic mouse model, in which c-myc 
overexpression in B lymphocytes causes an 
increase in cell size in the absence of cell 
division (Iritani et al., 1999).  B lymphocytes 
proliferate in vitro after activation with anti-
CD40 plus interleukin-4 (IL-4), and this 
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proliferation is accompanied by a cell size 
increase.  c-Myc is indispensable for B cell 
growth after antigen stimulation (de Alborán 
et al., 2001).  In addition, c-myc inactivation 
in liver leads to a decrease in hepatocyte 
size (Baena et al., 2005) and regulates 
cell ploidy (Conner et al., 2003).  c-Myc 
also regulates body size; hypomorphic 
mice expressing reduced c-Myc levels 
show smaller body size due to a decrease 
in cell number in many organs, without 
affecting cell size (Trumpp et al., 2001).
1.7.3 Role in induced apoptosis
c-Myc-induced apoptosis was first 
recognized in studies of the 32D.3 myeloid 
progenitor cell line. Enforced c-Myc expression 
had no effect on 32D.3 cells in normal growth 
conditions; in the absence of growth factors 
(IL-3), however, c-Myc overexpression 
accelerated cell death (Askew et al., 1991).
Growth arrest is accompanied by 
rapid downregulation of c-Myc expression, 
leading to study of the ability of cells 
constitutively expressing c-Myc to arrest 
when deprived of mitogens.  In a fibroblast 
cell line (Rat-1), which expresses human 
c-Myc under a constitutive promoter, serum 
deprivation conditions lead to complete 
growth arrest and cells  enter a G0/G1-like 
state.  The authors also observed that cells 
with higher c-Myc levels are more prone to 
enter apoptosis.  The first cell deaths were 
observed within 30 min of serum withdrawal 
and continued at a more or less constant 
rate (Evan et al., 1992).  This demonstrates 
that c-Myc has a role in cell death induced 
by the absence of necessary growth factors.
Mutations in different c-myc regions 
demonstrated complete concordance 
between those regions required for apoptosis 
and those necessary for cotransformation 
and proliferation.  These regions include 
the bHLH-LZ at the C terminus and part of 
the N-terminal region (Evan et al., 1992).
c-Myc expression sensitizes cells to 
a wide range of pro-apoptotic stimuli such 
as hypoxia, DNA damage and depleted 
Figure I5 
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survival factors, as well as enhancing 
sensitivity to signaling through CD95 
(Fas receptor) (Hueber et al., 1997), TNF 
(Klefstrom et al., 1994) and TRAIL (Lutz et 
al., 1998).  Various pathways are implicated 
in c-Myc-induced apoptosis; cMyc induces 
cytochrome c release from the mitochondria 
into cytosol by direct activation of the 
pro-apoptotic molecule Bax (Juin et al., 
2002; Soucie et al., 2001).  Bax creates 
pores in the mitochondrial membrane, 
resulting in mitochondria outer membrane 
permeabilization (MOMP).  Cytocrome c 
associates with a protein termed apoptotic 
protease-activating factor 1 (APAF-1) to 
create the apoptosome, which acts as 
a scaffold for activating procaspase-9. 
Caspase 9 is activated in the presence of 
ATP, leading to activation of the downstream 
caspase cascade, including caspase-3, 
which leads to protein degradation, 
cell disassembly and death (Figure I6).
Another apoptotic pathway is 
mediated by CD95/Fas signaling, which 
leads to recruitment of the Fas-associated 
death domain (FADD).  FADD binds 
procaspase-8, which auto-activates and 
triggers caspase cascade activation.  TNF 
receptor ligation results in activation of 
RIP and signaling via FADD.  c-Myc can 
also activate apoptosis through indirect 
activation of p53 via ARF (Zindy et al., 1998).
Anti-apoptotic signals such as 
Bcl-2 and Bcl-xL reside in the outer 
mitochondrial membrane and block 
Figure I6 
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MOMP through sequestration of BAX or 
binding to APAF-1 to prevent caspase 
9 activation (Pelengaris et al., 2003).
The complex interrelationship between 
c-Myc and apoptosis is determined by 
several factors, including cell type, tissue 
location and the presence or absence of 
additional mutations in other pro- and anti-
apoptotic genes (Pelengaris et al., 2003).
1.8 c-Myc in B cell differentiation
c-Myc functions at a critical decision 
point of cell growth to promote proliferation 
and block terminal differentiation.  c-Myc 
is present in dividing cells, and its 
donwregulation is reported to accelerate 
terminal cell differentiation (Chang et al., 
2000; Henriksson et al., 1996), whereas 
ectopic c-Myc expression has the opposite 
effect in several cell types, both in vivo and in 
vitro (Lachman et al., 1986; Iritani et al., 1999).
C/EBPα, which is necessary for 
myoblast commitment to the granulocytic 
lineage, forms a complex with E2F/pRB 
that represses c-myc expression (Johansen 
et al., 2001).  Another example of c-Myc 
downregulation in terminally differentiated 
cells is found in plasma cells (PC).  c-Myc 
transcription in PC is repressed by the 
plasmacytoma repressor factor Blimp-1 (B 
lymphocyte induced maturation protein). 
Blimp-1 overexpression in a pro-monocytic 
cell line results in repression of c-myc; this 
drives these cells to macrophage and B 
cell generation (Lin et al., 1997; Chang et 
al., 2000).  Repression of c-Myc is thus a 
component of the Blimp-1 program of terminal 
B cell differentiation.  These data indicate 
that c-myc is involved in the programs 
for differentiation to specific cell fates.
As the focus of this thesis is the B 
cell differentiation process, we will review 
some work in this area.  c-Myc is expressed 
throughout the B cell differentiation process 
at various levels.  c-Myc expression begins 
at the pro-B cell stage after IL-7 stimulation 
(Morrow et al., 1992).  It is also expressed, with 
N-myc, in large pre-B cells during maturation 
and expansion to the small pre-B stage 
(Zimmerman et al., 1990).  These findings 
prompted researchers to study c-Myc function 
in B cell development using murine models.
Gain-of-function studies in a mouse 
lymphomagenesis model (Eµ-c-myc mouse) 
have been a useful tool to reveal c-myc 
function in B cells.  In this mouse, the c-myc 
proto-oncogene is expressed under the 
control of the immunoglobulin heavy chain 
enhancer (Eµ); these mice show a blockade 
in pro/pre-B (IgM-) to immature B cell (IgM+) 
transition in bone marrow, causing a reduction 
in mature B cells in spleen (Iritani et al., 1999).
Loss-of-function experiments were 
also used to study the role of c-Myc in B cell 
differentiation.  Germline c-myc inactivation 
causes embryonic lethality before gestation 
day E10.5, due to abnormalities in growth 
and in cardiac and neural development, 
among other defects (Davis et al., 1993). 
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N-myc germline deficiency is also embryonic 
lethal (Charron et al., 1992).  c-Myc-deficient 
cells are nonetheless able to proliferate and 
embryos are viable until E10.5, probably due 
to rescue of c-Myc functions by other myc 
family members such as N-Myc.  Insertion 
of the N-myc coding sequence in the c-myc 
locus, replacing the c-myc gene, rescued 
embryonic viability, so N-Myc can replace 
c-Myc function in vivo (Malynn et al., 2000). 
To study the effect of c-Myc deficiency in 
adult tissues, the use of conditional knockout 
(KO) mice became necessary.  The c-mycflox 
model in which Cre/LoxP technology allows 
c-myc deletion in adult mice was generated 
in 2001 (de Alborán et al., 2001).  In these 
mice, B lymphocyte proliferation in response 
to anti-CD40 + IL-4 is severely impaired; B 
cells accumulate in G0/G1 phase, and show 
similar size after activation to that of non-
activated cells.  These c-myc-deficient B 
cells show upregulation of p27 (de Alborán 
et al., 2001) and are resistant to CD95-
induced cell death because they express 
lower surface levels of CD95 and CD95L 
after mitogenic stimulus (de Alborán et 
al., 2003).  The important role of c-Myc in 
B cell differentiation was also observed in 
the double N-myc/c-myc KO, in which the B 
cell lineage is blocked at the pro- to pre-B 
transition (Habib et al., 2007).  Our laboratory 
recently reported that c-Myc regulates early 
B cell differentiation through the transcription 
factor EBF1, by direct binding of the c-Myc 
protein to the promoter region of ebf1 
gene (Vallespinós et al. 2011, in press).
All these findings connect c-myc 
with early B cell differentiation.  c-Myc 
expression nonetheless remains constant 
until the mature B cell stage, and is not 
downregulated until mature B cells fully 
differentiate to PC.  The aim of this thesis 
is to study the function of c-Myc in terminal 
B cell differentiation, as it might have 
an role beyond cell proliferation in early 
stages of this process, before repression by 
Blimp-1.  There are no in vivo studies that 
connect c-Myc with an important function 
in plasmacytic differentiation other than 
proliferation.  There is only one previous study 
using a mature B cell lymphoma line (BCL-
1) in vitro, which reported that repression of 
c-myc is necessary but not sufﬁcient for PC 
differentiation, demonstrating the existence 
of additional Blimp-1 target genes essential 
for this process.  Constitutive expression of 
c-Myc blocked plasma cell differentiation. 
Furthermore, ectopic expression of cyclin 
E impaired terminal differentiation of BCL-1 
cells in response to cytokine, and mimicked 
the effects of c-Myc in proliferation, 
indicating that abrogation of proliferation 
is indispensable for BCL-1 differentiation. 
Inhibition of c-Myc by a dominant negative 
form was nonetheless insufﬁcient to drive 
BCL-1 differentiation (Lin et al., 2000).
Nevertheless this work leaves an 
open door to the requirement for c-Myc 
expression at early stages of terminal B 
cell development, necessary for activating 
an indispensable pathway for full PC or 
memory B cell generation.  c-Myc might 
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act as a key transcription factor, not 
only as a protein to be eliminated at the 
termination of B lymphocyte differentiation.
1.8.1 Early B cell differentiation
Early B cell differentiation is a tightly 
regulated process that occurs in fetal liver 
or adult bone marrow (BM), from common 
lymphoid progenitors (CLP) to mature B 
cells.  It is linked to the V(D)J rearrangement 
state of the immunoglubulin heavy (IgH) 
and light (IgL) chain genes.  This process 
is accompanied by expression of several 
surface molecules, which allow identification 
of different B cell subsets through maturation 
from pre-pro-B to mature recirculating B cells 
(Hardy et al., 2001).  Early development 
depends on several transcription factors, 
including early B cell factor (EBF), E2A 
and paired box protein (PAX5) (Busslinger 
et al., 2004).  Successful rearrangement of 
the IgH gene segments in pro-B cells leads 
to the pre-B cell stage, in which pre-B cell 
receptor (pre-BCR) expression starts.  This 
is a checkpoint for expansion, and allows 
rearrangement of IgL gene segments, which 
in turn triggers surface IgM expression.  The 
cell becomes a naïve mature B cell which, 
after surviving negative selection, exits the 
bone marrow and further differentiates in 
secondary lymphoid organs such as spleen. 
These recent BM emigrants in the periphery 
are called transitional B cells, which are 
divided into transitional stages T1 and T2 
(Chung et al., 2003).  A small fraction of 
these transitional B cells home to the splenic 
marginal zone (MZ) and do not recirculate, 
but most T2 cells mature into follicular B cells, 
a B cell subset that recirculates between 
the follicles, lymph nodes and BM until 
they die, or encounter antigen and mature 
completely (Shapiro-Shelef et al., 2005).
B lymphocytes become antibody-
secreting cells (ASC), the mediators 
of the humoral response.  A productive 
antigen encounter will result, among other 
things, in multiple rounds of division and 
secretion of antigen-specific antibody to the 
serum and interstitial fluids.  After antigen 
stimulation, B cells will acquire the ability 
to become terminally differentiated cells: 
plasmablasts, short and long-lived PC or 
memory B cells (Manz et al., 2005).  Which 
B cell subset is generated depends on the 
nature of the antigen, dose and location 
of encounter (Shapiro-Shelef et al., 2005).
1.8.2 Terminal B cell 
differentiation
Terminal B cell differentiation takes 
place in secondary lymphoid organs, which 
include lymph nodes, Peyer’s patches, 
tonsils and adenoids, mucosa-associated 
lymphoid tissue, and the white pulp of spleen. 
These organs provide points of intersection 
between naïve and antigen-experienced 
lymphocytes, accessory cells, molecules 
from the innate immune system and antigens.
We will focus our study of terminal 
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follicles, which are spheroid aggregates 
located in the surroundings of the PALS, 
where we also find follicular dendritic cells 
(FDC) and a few T cells (Figure I7).  The 
MZ also contains macrophages and a small 
population of memory B cells in rodents.
Antigens are classified as T-dependent 
(TD) or T-independent (TI), based on their 
capacity to induce a response in nude 
(athymic) mice.  TI antigens are subdivided 
into TI-1, such as LPS or endotoxin, and 
TI-2, such as bacterial polysaccharides.
MZ B cells 
(IgMhiIgDloCd21hiCD21hiCD23lo) surround 
the marginal metallophilic macrophage ring 
B cell differentiation in the murine spleen. 
The spleen is divided into red pulp, where 
macrophages remove senescent red 
blood cells from the circulation, and the 
white pulp, comprising follicles, T cell 
zones (periarteriolar lymphoid sheaths or 
PALS) and MZ.  B and T cells segregate 
into separate regions of this organ.
B cells migrate from the BM to the 
spleen, where they enter via the blood.  They 
are called transitional B cells, identified by the 
surface phenotype IgMhiIgD+CD23intCD21int-
hi.  These T1 and T2 cells can either be 
recruited into the MZ, located between 
the white and red pulp, or organize into 
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identified by the MOMA-1 antibody (Kraal et 
al., 1986), and provide an early response 
to bacteria and mainly to TI-2 antigens. 
This triggers a burst of proliferation and 
generation of plasmablasts or short-lived 
PC foci in extrafollicular regions along the 
periphery of the PALS.  Circulating mature 
follicular B cells activated after antigen 
stimulation can also form extrafollicular 
foci and give rise to plasmablasts and 
short-lived PC.  These short-lived PC have 
not undergone somatic hypermutation 
(SH) or class switch recombination 
(CSR), and die by apoptosis in situ.
When follicular B cells 
(IgMloIgDhiCD21loCd23hi) encounter antigen 
and receive T cell help, they are able to form 
germinal centers (GC).  The choice between 
the formation of extrafollicular foci or to enter 
a germinal center seems to be based on the 
strength of antigen recognition by the BCR 
(Paus et al., 2006).  Germinal centers are 
specialized follicular areas that arise from a 
small number of precursors derived from B 
cells activated in the T zone by TD antigens, 
which undergo massive proliferation.  They 
give rise to centroblasts that populate 
the dark zone, proximal to the T cell area. 
Centroblasts exit the cell cycle to become 
centrocytes, which are located close to 
mature FDC in the light zone, in the opposite 
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pole or the GC.  In the GC, B cells undergo 
several rounds of SH and CSR.  CSR consists 
of DNA rearrangement events in which 
deletion replaces one Ig heavy constant 
region gene segment (typically µ) with a 
more 3’ gene segment (γ, ε or α) to change 
the effector properties of the Ig secreted.  SH 
is a unique mutation mechanism targeted to 
the variable regions of Ig genes that leads 
to affinity maturation, hence the specificity 
for the recognized antigen is increased.
The GC response peaks between 
day 10 and 14 and then diminishes. 
This reaction gives rise to long-lived 
PC and memory B cells which have 
undergone SH and CSR (McHeyzer-
Williams et al., 2001; Vinuesa et al., 2001; 
Shapiro-Shelef et al., 2005) (Figure I8).
1.8.3 Subpopulations
1.8.3.1 Plasmablasts
Plasmablasts are short-lived cycling 
ASC that are found in extrafollicular foci 
and resemble ASC generated after in 
vitro antigen stimulation.  They are an 
intermediate stage between activated B 
cells and PC, with morphology similar 
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to proliferating blast cells coupled to the 
ability to secrete low amounts of antibody, 
retaining some B cell characteristics such 
as B220 and CD19 expression (Figure I9).
1.8.3.2 Plasma cells
Plasma cells are fully differentiated 
cells of the B cell lineage that have acquired 
the ability to secrete large amounts of 
antigen-specific antibody.  They can be 
classified as short-lived PC, formed in 
extrafollicular areas such as the MZ of the 
spleen in response to TD and TI antigens, 
with a life span of a few days or weeks, and 
long-lived PC, generated after T-dependent 
stimulation in follicular regions, with a half life 
of months to years in the absence of antigen 
or cell division.  If these long-lived cells have 
been generated in GC, they undergo the 
processes of SH and CSR, and will hence 
secrete high-affinity switched antibody. 
The mechanism by which PC are selected 
to become a long-lived population could 
be stochastic selection by their ability to 
inhabit the limited number of environmental 
niches that support their survival.
Terminally differentiated PC do 
not proliferate and they express the 
proteoglycan Syndecan-1 (Synd-1 or 
CD138) on their surface, which is a heparan 
sulfate proteoglycan that participates 
in cell adhesion and is used as a cell 
surface marker to identify PC populations 
(Sanderson et al., 1989), accompanied by 
downregulation of B220 in membrane, so 
we can identify the PC subset by the surface 
phenotype B220lo/- Synd-1+ (Figure I9).
1.8.3.3 Memory B cells
Memory B cells are formed after 
T-dependent antigenic stimulation and 
express class-switched immunoglobulin 
(Ig) on their surface, but do not secrete 
antibody.  Memory B cells provide rapid 
recall by quickly becoming PC that secrete 
high-affinity Ig after secondary antigenic 
challenge.  They provide defense to antigens 
for years or even the organism’s entire life, 
because they remain in their survival niches 
even without the presence of antigen. 
These cells are generated in the spleen, 
among other secondary lymphoid organs. 
Most models of post-germinal center B cell 
development posit that cells destined to 
become PC and memory B cells develop 
separately.  An alternative possibility is that 
there is a single developmental pathway, 
beginning with memory cells and progressing 
to plasmablasts and PC.  There is no firm 
evidence in this controversy, but the fact that 
Blimp-1 is dispensable for memory B cell 
generation, acting only in the memory-to-
plasma cell step, suggests different pathways 
for plasma and memory B cell differentiation.
1.8.4 Transcriptional control of 
terminal B cell differentiation
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PC are high producers of soluble 
antibody, hence they are crucial for an efficient 
humoral response.  Activation of mature B 
cells, differentiation to secretory cells and 
their survival must be tightly regulated. 
The transcription program controlling gene 
expression during B cell differentiation 
and activation versus PC differentiation 
are mutually exclusive.  This exclusion is 
achieved by the participation of stage-specific 
factors that repress other factors needed for 
the alternative developmental state (Calame 
et al., 2003), ensuring a solid unidirectional 
pathway once B cells are committed 
towards fully differentiated ASC.  This 
network is composed of a few transcription 
regulators with a complex regulation 
between them, and some hierarchical 
relationships still remain unclear. The most 
relevant factors in this regulatory pathway 
are Blimp-1, Xbp-1, Irf4, Bcl-6 and Pax5.
1.8.4.1 Blimp-1
The 856-amino-acid Blimp-1 (B 
lymphocyte induced maturation protein) 
was first identified as a repressor of the 
human interferon-β promoter (Keller et al., 
1991) and subsequently described in 1994 
when the B cell lymphoma cell line BCL1 
was activated with IL-2 and IL-5 to promote 
Ig secretion.  The authors found only 1% 
of genes whose expression changed after 
comparison with non-activated BCL1 cells, 
and Blimp-1 was one of about 20 novel 
cDNAs isolated (Turner et al., 1994).  Its 
mRNA rises five-fold rapidly after activation. 
The protein Blimp-1 encoded by the gene 
prdm1, is a transcriptional repressor that has 
five Krüppel-type zinc motifs, proline-rich 
(PEST) sequences that increase sensitivity 
to intracellular degradation, and acidic 
regions.  This nuclear protein is not present 
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in fibroblasts, pre-T, T cells, pro-B or pre-B 
cells.  Expression in B cells is either absent or 
at very low levels compared to those of PC. 
Transfection of Blimp-1 into B cell lymphoma 
lines leads to plasma B cell differentiation, 
accompanied by induction of J chain 
mRNA, Ig secretion, Synd-1 upregulation 
and increased cell size (Turner et al., 1994).
Blimp-1 was considered the ‘master 
regulator’ of PC generation because its 
expression was reported to be necessary 
and sufficient to initiate and establish PC 
differentiation (Shapiro-Shelef et al., 2003). 
Blimp-1 is induced by antigen-driven PC 
differentiation, and its overexpression 
can drive mature B cells to PC (Turner et 
al., 1994).  It was nonetheless reported 
that commitment and initiation of ASC 
differentiation is independent of this 
transcription factor, although it is indeed 
essential for subsequent high Ig production 
and full PC differentiation.  The first event 
that triggers ASC differentiation is the 
downregulation of pax5, allowing the 
derepression of PC-specific genes such as 
xbp1, flt3, embigin and IgJ, to proceed to a 
state called the pre-plasma cell.  These cells 
are Synd-1- but secrete low levels of Ig in the 
absence of Blimp-1, suggesting that these 
cells had indeed initiated ASC differentiation; 
however, they failed to upregulate irf4. 
Transduction of these cells with Irf4 did not 
restore normal igJ, xbp1 or endogenous 
irf4 levels, suggesting that Blimp-1 
controls factors other than irf4 to promote 
ASC differentiation (Kallies et al., 2007).
Blimp-1 directly represses c-myc 
transcription (Lin et al., 1997), which 
explains cell cycle cesation in PC.  Blimp-1 
also inhibits pax5, allowing Xbp-1, J chain 
and Ig heavy chain transcription, which 
induces Ig secretion (Shaffer et al., 2004). 
Synd-1 is induced after Blimp-1 expression 
(Turner et al., 1994), Blimp-1 participates in 
generation of both long- and short-lived ASC 
and its expression is required for memory-to-
PC transition after re-exposure to antigen, 
but it is dispensable for memory B cell 
generation (Angelin-Duclos et al., 2000).
The prdm1 gene has two intronic 
regions that confer transcriptional repression 
mediated by Bcl-6 binding (Tunyaplin et 
al., 2004).  Bcl6 must be downregulated 
after GC reaction to allow the initiation 
of the Blimp-1 differentiation program.
1.8.4.2 Xbp-1
Xbp1 is a basic-region leucine zipper 
protein positively-acting transcription 
factor of the CREB/ATF family (cyclic 
AMP response element binding protein/
activating transcription factor) which 
is ubiquitously expressed (Liou et al., 
1990).  Overexpression of Xbp1 in BCL1-
3B3 cells triggers Synd-1 expression and 
CD44 downregulation, identical to the 
effect caused by Blimp-1 overexpression 
in these cells (Reimold et al., 2001).
Xbp1 germline deletion is embryonic 
lethal due to severe liver hypoplasia that 
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results in fatal anemia (Reimold et al., 
2000).  Analysis of xbp1-/-;rag2-/- chimeric 
mice showed normal B cell proliferation, GC 
formation and Blimp-1 expression, but they 
were devoid of PC.  They showed a severe 
Ig secretion defect, demonstrating that this 
factor is necessary for PC differentiation and 
that Blimp-1 does not compensate for the 
lack of Xbp1 (Reimold et al., 2001).  A similar 
phenotype was described in xbp1fl/fl;cd19cre/+ 
mice, which present very low Ig levels even 
in response to stimuli due to a lack of µS 
upregulation.  However, the genetic program 
of PC development is unaltered, and IRF4, 
Blimp-1 and Pax5 mRNA levels as well 
as Synd-1 expression are normal.  Xbp1 
was nonetheless shown to be dispensable 
for memory B cell generation (Todd et al., 
2009), suggesting later Xbp1 intervention 
after PC commitment to allow the changes 
in secretory apparatus and cell morphology 
needed for large-scale Ig secretion.  Xbp1 
mediates increase in cell size, lysosome 
content, mitochondrial mass and function, 
as well as protein synthesis, to establish 
the phenotype of a secretory cell.  Xbp1 is 
also implicated in the function and survival 
of secretory cells other than PC such as 
exocrine gland acinar cells and Paneth 
cells (Kaser et al., 2008), and is associated 
with the UPR (unfolded protein response).
UPR is elicited by overexpression or 
misfolding of endoplasmic reticulum (ER) 
proteins (Harding et al., 2000).  This ER stress 
is transduced by IRE1, a transmembrane ER 
protein that is autophosphorylated when BiP 
chaperone binds to misfolded proteins and 
releases IRE1 to allow its multimerization 
and kinase activity.  IRE1 also has 
endoribonuclease activity, which mediates 
postranscriptional processing of Xbp1 
mRNA, giving a as result the active form of 
Xbp1.  Xbp1 in turn activates transcription of 
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UPR genes, involved in protein entry in the 
ER, folding, glycosylation, ER-associated 
degradation (ERAD) and vesicular trafficking 
(edem, dnaJc3, dnaJb9, hspa5, cope) (Cox 
et al., 1996; Travers et al., 2000; Shaffer et 
al., 2004).  UPR is also mediated by two other 
signaling pathways via activation of PERK 
and ATF6.  PERK normally interacts with BiP, 
but this association is broken by ER stress; 
PERK then phosphorylates the translation 
initiator eIF2α, which mediates global protein 
synthesis inhibition and activates ATF4 
transcription factor.  ATF4 in turn activates 
other UPR genes such as chop and BiP 
(Harding et al., 2001).  ATF6 is also released 
by BiP and exported to the Golgi, where it is 
processed and upregulates expression of ER 
chaperones and Xbp1 (Yoshida et al., 2000).
Xbp1 expression is strongly inhibited 
by Pax5; this accounts for high Xbp-1 
expression levels in PC once Pax5 is no 
longer expressed (Reimold et al., 1996).  Its 
expression is induced by IL-4 during B cell 
activation, whereas production of the spliced 
form is dependent on Ig synthesis levels during 
PC differentiation (Iwakoshi et al., 2003).
1.8.4.3 Irf4
Irf4 (also known as LSIRF/ICSAT/
Pip/MUM1) is a member of the interferon 
regulatory family of transcription factors 
containing a DNA binding domain with five 
conserved tryptophan repeats (Taniguchi et 
al., 2001).  In contrast to other IRF family 
members, Irf4 expression is not induced 
by interferons.  Its expression is limited 
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to lymphocytes, dendritic cells (DC) and 
macrophages (Eisenbeis et al., 1995).  It 
is induced by antigen receptor or mitogen 
stimulation and its expression is maximum 
in PC (Matsuyama et al., 1995).  Irf4 
interacts with other partners such as PU.1, 
SpiB, Irf8, Stat6 and E2A to modulate its 
transcriptional activity (Eisenbeis et al., 1995).
Irf4 is first expressed in immature 
B cells together with Irf8, and then is re-
expressed in some centrocytes and in PC 
(Falini et al., 2000).  Irf4 controls processes 
of PC differentiation and isotype switching by 
induction of Blimp-1 and activation-induced 
deaminase (AID), respectively.  Irf4 KO mice 
show low serum Ig, although the mature B cell 
subset is unaffected, GC center formation is 
normal, and they show normal proliferation 
levels and induction of activation markers 
CD25, CD69, CD80 and CD86.  Irf4-deficient 
B cells are compromised for CSR and Ig 
secretion, they lack post-GC PC and are 
unable to differentiate from memory B cells 
into PC (Mittrucker et al, 1997; Sciammas et 
al, 2006; Klein et al, 2006).  Irf4 coordinates 
PC differentiation and CSR in a Irf4 graded 
expression manner; low Irf4 levels are 
sufficient to activate its target AID, whereas 
only PC with very high Irf4 expression are 
able to induce Blimp-1 and fully differentiate 
into Synd-1+ ASC.  Restoration of AID in 
Irf4-deficient cells induced CSR, although 
rescue was incomplete, suggesting that Irf4 
might regulate other genes implicated in 
isotype switching.  Irf4 transduction, even 
with a mutant that is unable to interact with 
PU.1 or SpiB, restored Ig secretion and 
CSR, indicating that these Irf4 functions are 
independent of its transcription partners. 
Irf4 is not reported to bind directly to the 
aicda gene (encoding AID), but binds to a 
region between exons 5 and 6 of the prdm1 
gene (Klein et al., 2006; Sciammas et al., 
2006).  Irf4 is reported to act downstream 
of Blimp-1, as it is expressed in a GC B 
cell population that already expresses 
Blimp-1; Irf4 is also activated by ectopic 
Blimp-1 expression in a B lymphoma (M12) 
(Sciammas et al., 2004), suggesting an 
autoregulatory loop between Irf4 and Blimp-1.
Irf4 binds to enhancers in the IgLκ 
and λ loci, and thus might induce high 
transcription of Ig genes.  It is not required for 
memory B cell generation, however (Klein et 
al., 2006).  Irf4 direct targets act in metabolic 
control, membrane biogenesis, cell cycle 
progression, cell death and PC differentiation.
It is not clear whether Irf4 alone is 
sufficient to drive Blimp-1 expression and 
trigger PC differentiation.  In the absence of 
Irf4, Blimp-1 expression is insufficient for PC 
differentiation.  The two transcription factors 
are thus non-redundant, essential for ASC 
formation and critical upstream activators 
of Xbp1.  Irf4 binds directly to the promoter 
of Bcl6 and downregulates its transcription 
(Saito et al., 2007), contributing to 
establishment of the PC transcription program.
Elevated Irf4 expression has been 
described in multiple myeloma, a malignancy 
of PC, and Irf4 knockdown was toxic to 
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these cells, resulting in cell death.  c-myc 
downregulation was reported after treatment 
with Irf4 small haipin RNA (shRNA), and 
chromatin immunoprecipitation (ChiP) 
demonstrated cMyc binding to a region of the 
Irf4 first intron, revealing a positive regulatory 
loop in which Irf4 and c-Myc mutually reinforce 
their expression (Shaffer et al., 2008).
1.8.4.4 Bcl-6
Bcl-6 (B Cell Lymphoma protein 6) was 
identified by its implication in chromosome 
translocations affecting chromosome 3q27 
in diffuse large cell lymphoma (DLCL) 
(Baron et al., 1993).  One-sixth of all 
B cell non-Hodgkin’s lymphomas have 
translocations of the bcl-6 gene, which is 
the most frequently translocated in these 
cancers (Dalla-Favera et al., 1999).  Bcl-6 
is a six Krüppel-type zinc-finger-containing 
transcriptional repressor (Chang et al., 1996).
It is expressed mainly by lymphocytes, 
with highest expression in GC, including all 
centroblasts and centrocytes (Cattoretti et 
al., 1995).  Nascent pre-GC cells upregulate 
Bcl6, migrate to the follicular area and form 
GC, while cells that do not upregulate Bcl-
6 after antigen encounter differentiate into 
plasmablasts in the PALS (Fukuda et al., 
1997).  Bcl-6 has at least two functions in 
GC, promoting cell cycle progression and 
inhibiting differentiation.  It also suppresses 
the cell’s intrinsic apoptotic response to DNA 
damage to allow GC B cells to sustain the 
DNA damage associated to AID-dependent 
CSR and V gene SHM (Phan et al., 2007).
Plasmacytic differentiation, both pre- 
and post-GC, occurs only in the absence of 
Bcl-6, since bcl-6 must be downregulated to 
allow Blimp-1 expression.  Other Bcl-6 target 
genes are CD44, CD69, cyclin D2, p27kip1 
and id2, although only cyclin D2 and blimp-1 
are direct Bcl-6 targets (Shaffer et al., 
2000).  Bcl-6 levels are maintained in GC 
by STAT (Signal Transducers and Activators 
of Transcription) activation and absence of 
BCR and CD40 signalling.  The ASC program 
starts when Bcl-6 levels are downregulated 
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by several mechanisms: by MAPK (Mitogen-
Activated Protein Kinases) phosphorylation 
and subsequent degradation after BCR 
stimulation (Moriyama et al., 1997) and Irf4-
dependent inhibition of bcl-6 transcription 
via NFκB (Nuclear Factor-κB) activation 
following CD40 stimulation (Saito et al., 2007).
Bcl-6 mutant mice fail to form 
GC during a T cell-dependent immune 
response, have increased PC formation 
after immunization, and develop a fatal 
inflammatory disease (Dent et al., 1997). 
Their B cells have an activated surface 
phenotype (in the absence of immunization), 
with downregulation of surface IgM, CD69 
and CD44 expression, although they fail 
to complete plasmacytic differentiation 
(no Synd-1 expression or downregulation 
of MHC (Major Histocompatibility 
Complex) class II) (Shaffer et al., 2000).
1.8.4.5 Pax5
Pax5 (PAired Box protein 5) was first 
identified as a homolog of the sea urchin 
protein TSAP (Tissue-Specific Activator 
Protein) and was originally named BSAP 
(B cell lineage-Specific Activator Protein). 
It binds DNA by a bipartite 128–amino-
acid paired domain, which shows similarity 
with some homeobox-containing proteins 
from D. melanogaster, and can function 
as transcriptional activator or repressor. 
It has a role in B cell differentiation 
and also in neural development and 
spermatogenesis (Adams et al., 1992).
Pax5 is expressed throughout B cell 
development and activates target genes 
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important for early B cell differentiation and 
activation, including Igα, CD19 and B-cell 
linker (BLNK) (Nutt et al., 2001; Horcher et 
al., 2001).  It also induces AID expression, 
necessary for CSR and SH in the GC 
(Gonda et al., 2003).  Pax5 represses 
xbp1, Igh, IgL and j chain expression, 
blocking the PC differentiation program 
(Reimold et al., 1996; Rinkenberger et al., 
1996; Singh et al., 1993).  Experiments by 
Kallies et al.. (Kallies et al., 2007) led to 
a model in which the PC program begins 
by inhibition of pax5  expression, allowing 
the change to new genetic programs and 
derepressing genes necessary for Ig 
secretion, although full ASC differentiation 
needs the expression of other transcription 
factors such as Blimp-1.  The factor(s) 
that modulate Pax5 levels nonetheless 
remain unknown.
Blimp-1 directly represses pax5 by 
binding to a site in its promoter.  Blimp-1 
is necessary and sufficient for Pax5 
repression during the PC differentiation 
program.  Enforced BSAP expression 
inhibits formation of IgM-secreting cells, 
although Blimp-1 is induced normally 
(Lin et al., 2002).  Pax5 repression is 
thus the first event necessary to shift 
from the early to late B cell transcription 
program, although other transcription 
factors must be expressed for further 
progress in differentiation.  A summary of 
the transcription pathway controlling PC 
differentiation versus B cell activation is 
shown in Figure I15.
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2. Aims
To characterize the role of c-Myc in terminal B cell differentiation using a loss-of-function 1) 
murine model: generation of plasma cells and immunoglobulin secretion in vitro.
To characterize the immune response in c-Myc-deficient mice after immunization with 2) 
T-dependent and T-independent antigens.
To analyze the gene expression levels of the major transcription factors involved in 3) 
terminal B cell differentiation in the absence of c-Myc.
To rescue the wildtype phenotype by gain-of-function experiments overexpressing 4) 
potential cMyc targets.
Materials & Methods
3. Materials & Methods
3.1 Generation of c-myc flox/flox;cd19Cre 
/+;rosa26egfp/egfp Mice
The generation of the c-mycflox;cd19cre 
mice has been described previously (de 
Alborán et al., 2001; Rickert et al., 1997). 
Briefly, c-mycflox;cd19cre mice were bred 
with rosa26egfp mice (Mao et al., 2001) and 
progeny bred to yield homozygous c-mycflox/
flox;cd19cre/+;rosa26egfp/egfp mice (c-mycfl/fl) or 
heterozygous c-mycfl/+cd19cre/+rosa26egfp/
egfp mice (c-mycfl/+).  Mice were genotyped 
using a PCR-based analysis of tail 
genomic DNA with specific primers: 
Flox 3’ (TTTTCTTTAAGATTGCTGAC) and 
Flox 5’ (TAAGAAGTTGCTATTTTGGC) to 
detect flox alleles in c-myc locus
CD19.8 (AATGTTGTGCTGCCATGCCTC) and 
CD19.9 (GTCTGAAGCATTCCACCGGAA) for 
CD19 wt allele
Cre3 (CAATTTACTGACCGTACA) and Cre4 
(CATCGCCATCTTCCAGCA) to detect Cre 
recombinase
GFPI (GGCTTAAAGGCTAACCTGTG), GFPIII 
(GGAGCGGGAGAAATGGATATG), Lacz1 
(GTGGTGGTTATGCCGATCG) and Lazc2 
(TACCACAGCGGATGGTTCGG) to ampli-
fy EGFP or wildtype (WT) alleles in rosa26 
locus.
3.2 Immunizations
For the study of T-dependent 
response in c-mycfl/fl and littermate control 
mice, 6- to 8-week-old, were immunized 
intraperitoneally (ip) with 200 µg of 2,4,6, 
Trinitrophenyl-Keyhole Limpet Hemocyanin 
(TNP-KLH) (Biosearch Technologies) in 
Alum adjuvant (Pierce) at ratio 1:1 in 0.2 
ml of phosphate-buffered saline (PBS).  For 
memory response, the same dose of TNP-
KLH was given 4 weeks after the initial dose. 
Mice were analyzed 12 days after secondary 
immunization for FACS and histology. 
Mice were bled weekly for serum ELISA.
For T-independent response mice were 
injected intravenously (iv) with 3µg of LPS 
(Sigma).  Mice were analyzed 3 or 7 days later
3.3 Flow Cytomery
Single cell suspensions were incubated 
in NH4Cl buffer for erythrocyte lysis and 
stained with a suitable dilution of surface 
anti-mouse antibodies in PBS with 2% fetal 
bovine serum (FBS).  Antibodies were from 
eBioscience (B220-Pecy7, GL-7-biotin, 
IgM-APC, CD38-Alexa700 and F4/80-APC); 
Pharmingen (CD23-PE, CD21-APC, CD69-
biotin and Gr1-APC); BD (CD138-PE, IgG1-
PE); Biolegend (B220-Pacific Blue and IgD-
Alexa647); Southern Biotech (IgD-biotin, 
IgE-biotin).  Biotynilated antibodies were 
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revealed with streptavidin-PE or streptavidin-
Pecy7 (Pharmingen).  To detect TNP-
specific memory B cells by FACS TNP-BSA-
biotin was used (Biosearch Technologies). 
Ant-human CD2-APC was from IOTest. 
 For cell cycle analysis cells were 
stained with propidium iodide using Coulter 
DNA PREP kit (Beckman Coulter) and 
following manufacturer’s instructions.
 A FACS Coulter flow cytometer 
was used for analysis and an EPICS-
ALTRA (Beckman Coulter) or FACS 
Aria (BD) were used for cell sorting 
3.4 B Cell Purification
 Freshly isolated splenocytes were 
stained with anti-B220-Pecy7 in PBS 
with 2% FBS.  B220+ GFP+ cells were 
purified (purity > 95%) for B cells culture 
with a Beckman Coulter sorter.  For gene 
expression analysis spleen cells were 
separated into B220+CD138-GFP+ and 
B220loCD138+GFP+ 3 days after activation.
3.5 B Cell Culture
 Splenocytes were suspended in 
NH4Cl buffer to lyse red blood cells, were 
stained with the corresponding antibodies 
and purified by sorting.  Purified spleen 
cells were plated at 106 cells/ml in RPMI 
with 15% FCS, β-mercaptoethanol, and 
penicillin/streptomycin.  T-independent 
stimulation was mimicked with 30 µg/
ml of lipopolysaccharide (LPS) (Sigma) 
and T-dependent stimulation with 20 ng/
ml recombinant mouse IL-4 (R&D) and 10 
ng/µl anti-CD40 antibody (Pharmingen). 
Activated cells and supernatants were 
harvested after 1, 3 or 4 days in culture.
3.6 ELISA
 To detect total IgM or IgG1 in culture 
supernatants 96 Immunosorp flat-bottomed 
plates were coated with purified polyclonal 
goat anti-mouse IgM (Southern Biotech) or rat 
anti-mouse IgG1 (clone A85-1, Pharmingen). 
Samples were plated in triplicates of 3-fold 
serial dilutions after blocking wells with 
PBS with 1% BSA.  Secondary antibody 
was anti-IgK-HRP (clone 187.1, Southern 
Biotech), it was developed with Sigmafast 
OPD (Sigma) and reaction was stopped 
with H2SO4  3M.  Plates were read at 495nm. 
For IgE plates were coated with purified 
anti-IgE and developed with biotinylated 
anti-IgE (Southern Biotech).  Finally, plates 
were incubated with streptavidin-HRP 
(Pharmingen) and developed as above.
 To measure TNP-specific antibodies 
in mice sera, plates were coated with TNP-
BSA(19) (Biosearch Technologies) 10mg/ml 
in PBS.  Plates were blocked with PBS with 
1% BSA and 5-fold serially diluted samples 
were plated.  Biotynilated anti-IgM, IgG2a 
(Southern Biotech) or IgG1 (Pharmingen) 
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were used as secondary antibodies.  For TNP-
specific IgE plates were coated with purified 
anti-IgE, plated samples and incubated with 
TNP-BSA-biotin (Biosearch Technologies), 
and developed as indicated above.
3.7 ELISpot
96 Immunosorp flat-bottomed plates 
were coated with purified polyclonal goat 
anti-mouse IgM (Pharmingen).  Plates were 
washed and triplicates of 3-fold serially 
diluted B220+GFP+ spleen cells were 
plated in RPMI with 1% FBS.  They were 
incubated at 37ºC in a CO2 incubator with 
95% humidity and 5% CO2 from 5 hours to 
over night to allow the formation of spots. 
Then cells were lysated with H2O containing 
0.05% Tween 20 (Tw) and washed in PBS 
0.05% Tw.  Plates were incubated with anti-
IgK-AP (Pharmingen) secondary antibody 
and developed with BCPI dissolved in 
AMP buffer (Sigma) added to 3% low melt 
agarose.  Plates were incubated 30 minutes 
at 37ºC to allow spots appear.  They were 
counted and spots surface measured in 
an AID Elispot Reader using AID software.
3.8 Immunoprecipitation and Western 
Blot
The supernatant corresponding to 5 
wells (1 mililiter of medium) was harvested 
3 or 4 days after anti-CD40 plus IL-4 
activation, and total secreted IgM was 
bound with polyclonal goat anti-mouse IgM 
(Pharmingen).  The remaining supernatant 
was immunoprecipitated again as a 
control.  Afterwards, IgM bound to antibody 
was precipitated with protein A/G Plus 
Agarose beads (Santa Cruz).  Beads were 
washed in PBS with proteinase inhibitors 
and bound protein was eluted at 95º C. 
Supernatants were subjected to SDS-PAGE 
in 10% Acrylamide/Bisacrilamide gel and 
semidried transfered to PVDF membrane. 
Blots were incubated with Policlonal goat 
anti-mouse IgM bound to HRP (Sigma) 
and developed with Chemiluminiscent 
Reagent Plus (Perkin Elmer).
3.9 Lentivirus production and infection
EF.CMV.hCD2t vector was obtained by 
replacing the RFP of the EF.CMV.RFP vector 
(Addgene) by the human CD2 truncated 
sequence (hCD2t) preceded by an IRES 
sequence (obtained from MSCV-IRES-
hCD2t vector), to get bicistronic mRNA and 
detect hCD2t expression by flow cytometry in 
infected cells.  Afterwards the Blimp-1 coding 
sequence was cloned upstream the IRES of 
the EF.CMV.IRES-hCD2t ‘empty’ vector to get 
the EF.CMV.Blimp-1-IRES-hCD2t full vector.
293T cells were seeded in 10 cm 
plates to reach about 80% of confluence 
the following day.  18 hours later they were 
cotransfected with EF.CMV.Blimp-1-IRES-
hCD2t or EF.CMV.IRES-hCD2t (empty) 
plasmids, pCMVdR8.74 and pMD2G 
(Vesicular stomatitis virus G protein or 
VsVg pseudotyping vector, that allows 
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high range of mammalian cells tropism and 
allows concentration of the viral particles by 
ultracentrifugation (Burns et al., 1993)), at 
ratios 5:5:2 µg.  The DNA transfection was 
performed with Jet PEI (at ratio 2:1) (Polyplus 
transfection).  Lentitviral supernatants were 
collected 36 and 60 hours post-transfection 
and filtered through a 45 µm low protein-
binding syringe filter (Pall, Life Sciences). 
Supernatants were concentrated 50x by 
ultracentrifugation in polyallomer tubes 
(Beckman) for 2 hours and 30 minutes at 
22.500 rpm in a SW 28 rotor (Beckman).
B220+GFP+ spleen cells were sorted 
and plated at 106 cells/ml in U-bottomed 
96-well plates in 100 µl of RPMI medium 
containing 15% heat-inactivated FBS, 1 mM 
L-glutamine, 1 mM penicillin/streptomycin 
and 50 mM β-mercaptoethanol.  They were 
infected with 100 µl of lentiviral supernatants, 
to get a multiplicity of infection (MOI) of about 
10 viral particles per cell, and incubated for 
2 hours and 30 minutes at 37ºC in a CO2 
incubator.  Cells were spinned and medium 
was replaced by fresh complete RPMI 
medium and supplemented with anti-mouse 
CD40 antibody (20 ng/ml) (Pharmingen) plus 
recombinant mouse IL-4 (10 ng/µl) (R&D). 
Transduction efficiency was monitored 
by flow cytometry at 72 or 96 hours post-
infection by surface hCD2t expression.
3.10 Immunohistochemistry
For paraffin sections, half spleens were 
fixated in paraformaldehyde (PFA) 4% in 
PBS at room temperature (RT) for 2-3 hours 
and then in ethanol 70% v/v at 4º C over 
night.  They were included in paraffin and 
5 µm sections were cutted in a microtome. 
They were deparaffined before staining with 
Harry’s Hematoxylin/Eosin solution (Sigma).
For Spleen cryosections mice were 
sacrificed 12 days after second immunization 
and half spleens were snap-frozen in 
isopentane prevoiusly cooled in liquid 
nitrogen.  Samples were kept at -80ºC until 
10 µm sections were cut in a cryostate.  They 
were fixed in acetone for 10 minutes at RT 
before staining. Cryosections were blocked for 
endogenous peroxidase activity in methanol 
70% v/v with 0.3% H2O2, for endogenous 
biotin with Avidin/Biotin blocking kit (Dako), 
and for inespecific antibody binding in 10% 
inactivated goat serum before staining.
Sections were stained with rabbit 
polyclonal anti-GFP (ab290, Abcam) or rabbit 
anti-Cre polyclonal antibody (Covance) plus 
monoclonal rat anti-mouse B220 (Southern 
Biotech) and biotynylated anti-MOMA1 
(Dianova) or PNA-biotin (Vector Labs).  As 
secondary antibodies we used goat anti-
rabbit IgG-HRP (Santa Cruz) or mouse 
anti-rat IgG labelled with Cy5.  Following 
secondary antibody incubation, sections 
were stained with Tyramide-FITC (for HRP 
development) (Perkin Elmer) and streptavidin-
Cyn3 (Jackson).  Slides were mounted 
in Vectashield with DAPI (Vector Labs). 
Images were taken in a Olympus Confocal 
microscope  or fluorescente microscope.
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4. Results
4.1 A mouse model to study B cell 
differentiation: cmycfl/fl;cd19Cre/+;rosa26efgp/
egfp mouse generation
To study the role of c-Myc in the 
generation of primary ASC in vivo and in vitro, 
we used our previously reported conditional 
c-mycfl/fl;cd19cre/+;rosa26egfp/egfp mouse model 
(c-mycfl/fl hereafter (de Alboran et al., 2001). 
In the c-mycfl/fl mouse, the coding exons of the 
c-myc gene are flanked by loxP sites (floxed), 
which are normally expressed before Cre-
mediated deletion.  We crossed these mice 
with the cd19cre strain, which expresses the 
Cre recombinase under the B lymphocyte 
lineage-specific cd19 endogenous promoter. 
In the progeny, Cre expression mediates 
c-myc deletion in B cells.  To distinguish 
and isolate deleted cells, we crossed cmycfl/
f;lcd19cre/+ mice with a previously described 
reporter strain in which the enhanced 
green fluorescent protein (EGFP) was 
inserted in the rosa26 locus, preceded by a 
floxed stop codon (Mao et al., 2001).  We 
thus obtained c-mycfl/fl;cd19cre/+;rosa26egfp/
Figure R1.  Mouse model for c-Myc deletion in B lymphocytes
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egfp mice, in which c-myc is deleted 
and the egfp reporter gene is activated 
specifically in B lymphocytes.  c-mycfl/fl 
mice therefore generate cMyc-deficient B 
lymphocytes that express GFP (Figure R1).
4.2 c-Myc is necessary for differentiation 
to B220losyndecan-1+ cells in vitro
To determine whether c-Myc is 
necessary for the generation of terminally 
differentiated B cells in vitro, we isolated 
B220+GFP+ cells from spleens of c-mycfl/
fl or cmycfll+;cd19cre/+;rosa26egfp/egfp (c-mycfl/+) 
control mice by cell sorting.  We first 
studied in vitro generation of plasma cells. 
Plasma cells downregulate the B220 B cell 
marker and express the heparan sulfate 
proteoglycan Synd-1, which recognizes 
extracellular matrix and groWTh factors 
and is expressed in ASC (Sanderson et 
al., 1989).  Plasmablasts generated in 
vitro can thus be identified by the surface 
phenotype B220lo/-Synd-1+.  Plasma cells 
can be generated by stimulation with LPS 
(which mimics a TI response) or anti-
CD40 plus IL-4 (TD-like activation).  Flow 
cytometry analysis showed that c-Myc-
deficient B lymphocytes did not generate 
B220loSynd-1+ cells after in vitro activation 
with LPS (22.2% vs 0.4%) or anti-CD40 
Figure R2.  c-Myc is necessary for the generation of B220loSynd-1+ cells in vitro.  Sorted 
B220+GFP+ spleen cells from c-mycfl/fl and c-mycfl/+ mice were activated with LPS (A) or anti-CD40 
plus IL-4 (B) and analyzed by flow cytometry after 4 days.  Data are representative of at least three 
independent experiments.
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plus IL-4 (14.2% vs 0.3%) (Figure R2A, B).
This blockade in plasmablast 
differentiation could be due to a lack of 
activation caused by c-Myc deletion. 
Nonetheless, c-Myc-deficient B lymphocytes 
(GFP+) in these cultures expressed surface 
levels of the activation marker CD69 similar 
to those of control cells (Figure R3 and de 
Alboran et al., 2001); c-Myc-deficient B cells 
were therefore able to respond to mitogenic 
stimuli. We concluded from these experiments 
that c-Myc-deficient B lymphocytes do not 
differentiate into B220loSynd-1+ cells in vitro.
      4.3 c-Myc deficient B cells show 
greatly reduced proliferation in vitro
 To analyze the ability of these c-Myc-
deficient B cells to proliferate, we counted 
cells at day 3-4 after in vitro activation with 
T-dependent or -independent antigens.  The 
B cell count after 4 days of activation was 
approximately 4-fold lower in homozygous 
wells than in control cultures (Figure R4B) 
and the B cells blasts formed were notably 
smaller in homozygous cultures (Figue R4C).
We assayed these cells by propidium 
iodide (PI) staining and FACS to study 
the B cell proliferation state.  As reported 
(de Alboran et al., 2001), c-Myc-deficient 
B lymphocytes showed a notable 
proliferation impairment after stimulation 
with either LPS or anti-CD40 plus IL-4 
(Figure R4A); only 13.2% of cells were in 
S-G2/ phase M in KO cultures, compared 
to 20.1% in control cells after activation 
with LPS, and 20.1% vs 50.4% when they 
were activated with anti-CD40 plus IL-4.
4.4  p27 deletion does not rescue 
proliferation in c-Myc-deficient B cells
The cell cycle inhibitory molecule 
p27kip is upregulated in these c-Myc-
deficient B cells (de Alborán et al., 2001); 
we therefore tested whether downregulation 
of p27 expression could restore proliferation 
rates in KO cells, which would allow us to 
Figure R3.  Normal CD69 expression in c-Myc deficient cells. CD69 surface expression in 
puriﬁed B220+GFP+ B cells 3 days after anti-CD40 plus IL-4 activation. Data represents one of 
three independent experiments.
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study whether, in conditions that  normalize 
proliferation in the absence of c-Myc, plasma 
cell differentiation would also be normalized.
We crossed the c-mycfl/fl and 
c-mycfl/+;cd19cre/+;rosa26egfp/egfp mice with 
p27knockout mice (Fero et al., 1996) to 
obtain double homozygous mice and control 
littermates.  Cell cycle analysis in B cells 
from these mice, when activated in vitro, 
did not show increased proliferation rates, 
either when measured by PI analysis or 
in cell counts (Figure R5).  p27 deficiency 
was thus unable to rescue the defective 
proliferation attributed to the lack of c-Myc.
4.5 c-Myc-deficient B lymphocytes 
generate ASC
 The absence of plasmablasts with 
the B220lo/-Synd-1+ surface phenotype in the 
c-Myc KO cultures indicated that these cells 
do not express typical surface markers, but 
Figure R4.  Deficient proliferation of c-Myc KO mature B cells.  A) Propidium iodide (PI) 
staining of sorted B220+GFP+ splenocytes 4 days after in vitro anti-CD40 plus IL-4 stimulation.  B) 
Cell counts from the cultures in (A), n = 9.  C) B cell blasts formed after activation as in (A).
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we tested whether functional Ig-secreting 
cells could be generated in the absence of 
Myc..  To determine whether c-Myc-deficient 
B lymphocytes generated ASC, we used 
ELISA to measure secreted IgM in culture 
supernatants of cells activated with anti-CD40 
plus IL-4 at day 4.  We detected comparable 
concentrations of secreted IgM in supernatants 
of mutant and control cells (91.7 vs 75.8 µg/
ml) (Figure R6A).  An additional assay that 
measures ASC production in vitro is ELISpot, 
which detects the number of functional 
secreting cells generated from pre-activated 
B cells in non-proliferating conditions, by the 
appearance of spots where cells secrete a halo 
of IgM.  In ELISpot, we found an average 6-fold 
decrease in the total number of ASC per well 
in cultures of c-Myc-deficient B lymphocytes 
compared to control cultures (697.9 + 335.6 
vs. 4396.3 + 1006.2 ASC/well) (Figure 
R6B).  We concluded that c-Myc-deficient B 
lymphocytes can generate some ASC in vitro.
To secrete similar amounts of IgM 
with a smaller number of ASC, mutant B 
lymphocytes must either secrete more IgM 
per cell and/or begin secretion earlier than 
control cells.  To test these possibilities, 
we used ELISpot to measure the amount 
of secreted IgM produced at different time 
points; secretion kinetics was comparable 
for mutant and control ASC, and reached 
maximum at day three (Figure R7A).  The 
timing of secretion was therefore not 
responsible for the amount of IgM observed in 
the cultures of c-Myc-deficient B lymphocytes.
We analyzed whether mutant ASC 
secreted more IgM per cell by measuring 
Figure R5.  p27 deficiency does not rescue proliferation in c-Myc-deficient B cells.  PI 
staining of sorted B220+GFP+ splenocytes 4 days after in vitro anti-CD40 plus IL-4 stimulation. 
Data  representative of 4 independent experiments; n = 8.
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Figure R6.  c-Myc-deficient B cells are able to secrete IgM in vitro.  A) Secreted IgM in 
culture supernatants of activated B220+GFP+ cells on day 4 after anti-CD40 plus IL-4 stimulation, 
as measured by ELISA.  c-mycfl/+, n = 14; c-mycfl/fl, n = 15, p = 0.3 (NS).  B) Number of IgM ASC/
well, quantiﬁed by ELISpot.  n = 9, ***p<0.001.
Figure R7.  c-Myc-deficient B cells hypersecrete IgM.  A) Kinetics of IgM ASC generation after 
anti-CD40 plus IL-4 stimulation of B220+GFP+ cells, analyzed by ELISpot at different times post-
activation; n = 6.  B)  IgM ELISpots at day 4 post-activation.  C) Quantiﬁcation of IgM antibody 
secreted per ASC.  D) Mean spot area at day 4. n = 3, **p<0.01.
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the area of the spots generated in ELISpot 
assays.  We observed a 1.5-fold increase in 
the spot area generated by c-Myc-deficient 
cells compared to control ASC (0.0502 + 
0.0058 vs. 0.0286 + 0.0004 mm2) (Figure R7B, 
D).  Cultures of c-Myc-deficient B lymphocytes 
showed an average of 6-fold fewer ASC than 
control cultures.  The average of secreted IgM 
per ASC should be therefore 3-fold higher 
in mutant than in control cells (661.0 + 55.9 
vs 219.9 + 19.7 µg/105ASC) (Figure R7C) 
when calculated from the combined ELISA 
and ELISpot results at day 4 post-activation.
To confirm these results using 
another technique, we immunoprecipitated 
secreted IgM from the culture supernatants 
of mutant and control cells and performed 
Western blots to detect soluble IgM.  c-Myc-
deficient B lymphocyte supernatants 
showed immunoprecipitated IgM amounts 
Figure R8.  Hypersecretory phenotype of c-Myc-deficient B cells is restricted to the IgM 
isotype.  A) IgM immunoblot of total secreted IgM immunoprecipitated with polyclonal anti-
mouse IgM antibody from supernatant of anti-CD40 plus IL-4-activated B220+GFP+ B cells at day 
3.  A second immunoprecipitation was performed to ensure total precipitation of secreted IgM; 
blot representative of three independent experiments.  B) Intracellular IgM staining of puriﬁed B 
lymphocytes activated as in (A).  Representative data for three independent experiments. Mean 
peak values were 20.3 + 0.8 (c-mycfl/+) and 52.3 + 8.8 (c-mycfl/fl mice), **p<0.01.  C,D) Amount 
of IgG1 or IgE in supernatants from cultures of B lymphocytes activated as in (A), quantiﬁed by 
ELISA; n = 8 for IgG1, n = 7 for IgE. ***p<0.001.
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comparable to those of controls, despite the 
reduced ASC numbers in the mutant cell 
population.  We performed a second IgM 
immunoprecipitation to assure all secreted 
IgM in supernatant had been precipitated, 
which confirmed total capture in the first phase 
(Figure R8A).  Finally, intracellular staining 
showed more intracellular IgM in c-Myc-
deficient B than in control cells (Figure R8B).
This hypersecretory effect was restricted 
to the IgM isotype, since the amounts of 
secreted IgG1 and IgE in culture supernatants 
of mutant cells were severely reduced in vitro 
(Figure R8C, D), consistent with the surface 
staining for IgG1 and IgE in cells activated 
with anti-CD40 plusIL-4 (not shown).
Based on these data, we concluded 
that c-Myc deficient B cells are able to 
generate ASC (although they do not stain 
for surface Synd-1) and that they secrete 
more IgM per cell than control cells.  Finally, 
CSR is severely impaired in these cells.
4.6 Gene expression of c-Myc-deficient 
ASC
Plasma cell generation is orchestrated 
by a tightly regulated cascade of transcription 
factors in which the program involved in 
terminal differentiation is mutually exclusive 
with the program that activates early B cell 
differentiation and activation.  We examined 
whether ASC generation by c-Myc-deficient 
B cells was characterized by activation of the 
transcription program involved in terminal 
B lymphocyte differentiation, and studied 
the expression of several key transcription 
factors.  We used qPCR to monitor gene 
expression kinetics of B220+Synd-1-GFP+ 
and/or B220loSynd-1+GFP+ cells from c-mycfl/
fl and c-mycfl/+ mice after in vitro stimulation 
with anti-CD40 plus IL-4 at days 1 and day 
3 post-activation.  B220loSynd-1+GFP+ cells 
are not yet generated at day 1, either in 
mycfl/fl or c-mycfl/+ cultures.  This population 
was generated and sorted in control 
samples at day 3, and c-Myc-deficient 
B cells did not generate Synd-1+ cells.
 The hallmark of terminal B cell 
differentiation is the activation of the 
transcriptional repressor Blimp-1, which 
is in part inhibited by the action of Bcl-6. 
We observed a three-fold increase in bcl-
6 levels from early stages activation and a 
three-fold reduction in pdrm1 (Blimp1) gene 
expression in B220+Synd-1-GFP+ c-Myc-
deficient cells compared to controls at day 
3 (Figure R9).  We found no significant 
changes in the levels of pax5 and the 
transcription factor xbp-1, which participates 
in Ig secretion and the UPR pathway (Figure 
R10).  The expression of Xbp1 is compatible 
with the Ig secretion observed in the c-Myc-
deficient ASC.  Expression of the ire-1 gene, 
responsible for xbp-1 splicing and activation, 
was normal in mutant B lymphocytes.
Irf4 gene expression, which is 
upregulated throughout plasma cell 
differentiation, controls AID expression and 
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thus SH and CSR, and also activates Blimp-1 
expression in normal cells.  Irf4 remained at 
basal levels in mutant cells even at day 3 
of activation, four times lower than that of 
B220+Synd-1+ WT cells on day 3 (Figure R9). 
This finding would explain the lack of Synd1+ 
cells (as described for the Irf4-deficient 
mouse model (Sciammas et al., 2006) and 
the extremely low rates of Ig switched cells. 
In another similarity to the Irf4 KO model, 
we found a very remarkable downregulation 
of the aicda gene in the c-Myc KO cells 
as compared to control cells at day 3 (80-
fold reduction) and even at early activation 
phases (day 1) in B220+ cells (six-fold 
reduction relative to controls) (Figure R9). 
The lack of appropriate Irf4 activation could 
in great part explain the phenotype observed.
 We analyzed the expression of some 
genes implicated in the UPR pathway (chap-
erones, ERAD genes, genes with secretory 
Figure R9.  Gene expression of the main transcription factors involved in terminal B cell 
differentiation in in vitro-activated c-Myc-deficient B cells.  A) Sorted B220+GFP+ splenocytes 
from c-mycfl/fl and c-mycfl/+ mice were activated with anti-CD40 plus IL-4 and re-sorted at days 
1 and 3 to isolate B220+GFP+ and/or B220loSynd-1+GFP+ cells.  Mutant cells did not generate 
B220loSynd1+GFP+ cells.  cDNA was prepared from the RNA isolated and qPCR performed. 
Control (black) and mutant cells (white).  Results were normalized to β-actin, n = 6.  B) Summary 
of the gene expression changes of some other genes grouped by functional criteria.
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function, etc.), including bip, edem1, perk, 
cope, and hspa5.  We found no clear differ-
ences in any of these genes that would ac-
count for the hypersecretory phenotype (Fig-
ure R10).  Moreover, we found no significant 
differences in the expression of genes from 
activation pathways such as STAT6 or NF-κB 
(Figure R10).
In addition, we detected no alteration 
in the ratio of secreted IgM heavy chain 
versus membrane heavy chain, as analyzed 
by RT-PCR (Fig R11); transcription 
of these Ig forms would thus not be 
responsible for increased IgM secretion. 
Therefore we are far unable to identify the 
mechanism underlying this phenotype.
We conclude from these results that 
B lymphocytes that lack c-Myc are able to 
Figure R10.  Gene expression profile of c-Myc-deficient B cells.  Expression levels of some 
genes implicated in the UPR pathway, secretion and plasma cell differentiation.  Analysis as in 
Fig. R9; n = 6.
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initiate the terminal B cell differentiation 
transcription program by expressing Xbp1 
and low levels of Blimp-1, but fail to reach 
the final differentiation steps (such as 
Synd-1 expression and CSR) due to lack 
of Irf4 expression and high Bcl-6 levels.
4.7 Impaired immune response in c-mycfl/
fl mice
c-myc gene deletion in spleen B 
lymphocytes permits study of the immune 
response in c-mycfl/fl mice.  GFP expression 
allowed us to trace c-Myc-deficient cells 
(GFP+) and distinguish them from non-deleted 
c-Myc WT cells (GFP-).  We immunized mice 
with TD antigens (TNP-KLH) and TI antigens 
(LPS) to study the immune response in the 
context of c-Myc deficiency.  Unimmunized 
c-mycfl/fl mice showed four-fold fewer B220+ 
lymphocytes in spleen than control mice 
(de Alboran et al., 2001) and figure R15B.
To study plasma cell generation in 
response to T-dependent and -independent 
antigens, the splenocytes of TNP-KLH or 
LPS immunized c-mycfl/fl and control mice 
mice were stained and analyzed at different 
times by flow cytometry.  As observed in vitro 
(Figure 1a, c), c-mycfl/fl mice did not generate 
c-Myc-deficient B220loSynd-1+GFP+ plasma 
cells after LPS challenge at day 3 post-
immunization (0.3% vs 1.8%); results were 
similar when mice were analyzed at day 7. 
This reduction in the PC population was 
also very marked when mice were analyzed 
12 days after TNP-KLH administration 
(0.4% vs 1.2%).  As a control, GFP- (non-
deleted, WT) cells from the same c-mycfl/
fl mouse generated B220loSynd-1+ plasma 
cells in response to both Tdependent and 
-independent antigens (Figure R12).  Similar 
to spleen, long-term plasma cells were 
nearly absent in the BM of c-mycfl/fl mice after 
TNP-KLH immunization (Figure R13A, B).
To test the ability of c-Myc-deficient 
mice to generate antigen-specific antibodies 
in response to in vivo immunization, we used 
a TNP-specific ELISA to measure all the 
isotypes generated by this stimulation (IgM, 
IgG1, IgE and IgG2a).  As deletion is not 
Figure R11.  Secreted and membrane IgM forms are transcribed at normal levels in cMyc-
deficient B cells.  Membrane and secreted IgM forms (µS and µM transcripts) were ampliﬁed by 
RT-PCR from sorted B220+GFP+ c-Myc-deﬁcient or control cells activated with anti-CD40 plus IL-4 
for 4 days.  Representative ﬁgure for two independent experiments.
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complete in the cmycflox;cd19cre/+;rosa26egfp/
egfp mice, we detected a few wild type cells 
even in homozygous mice.  Nevertheless, 
TNP-specific IgM was slightly increased in 
c-mycfl/fl mouse serum compared to control 
mice after a second antigen challenge 
(Figure R13C).  Consistent with our in vitro 
results, other isotypes (IgG1, IgE, IgG2a) 
were decreased in mutant mice (Figure 
R13C), although the differences observed 
Figure R12. c-Myc-deficient B cell do not generate B220loSynd-1+ cells or GC B cells after 
immunization.  A) Flow cytometry analysis of plasma cells from spleens of c-mycfl/fl and control mice 
immunized with LPS or TNP-KLH.  Experiment representative of three independent experiments. 
B) Absolute numbers of B220loSynd-1+ cells in (A).  Preimmune: c-mycfl/+(n = 6), cmycfl/fl (n = 4), 
*p<0.05; LPS: c-mycfl/+(n = 6), c-mycfl/fl (n = 7), ***p<0.001; TNP-KLH: (n = 4), *p<0.05.  C) Germinal 
center B cells were identiﬁed by GL-7 high expression in B220+ cells from spleen by flow cytometry 
(n mice).  D) Absolute numbers of GC B cells in (C).
Results
were not significant in any isotype analyzed. 
This could be explained by the leakiness 
of the deletion in this mouse model; a 
large part of the antibody measured in KO 
mouse serum might be derived from non-
deleted WT cells.  This would mask the 
Figure R13.  c-Myc-deficient mice do not generate long-term plasma cells in BM after TD 
immunization.  A) Lack of long-term plasma cell population in BM of TNP-KLH-immunized cmycfl/
fl mice.  Single cell suspensions from BM were prepared and stained for the surface markers B220 
and Synd-1.  B) Absolute numbers of B220loSynd-1+ cells in A.  n = 3, *p< 0.05 **p< 0.01.  C) ELISA 
for detection of TNP-speciﬁc Ig levels of distinct isotypes in sera of TNP-KLH-immunized mice at 
different times post-immunization.  For IgM and IgE, n = 9; for IgG1, n = 6; for IgG2a, n = 4.
Results
phenotype, as Ig from deleted and non-
deleted cells cannot be distinguished by 
this method.  Based on these data, we 
cannot rule out that the secretion phenotype 
observed in vitro is found in vivo as well.
From the results of the immunization 
experiments, we concluded that c-Myc 
is necessary for the generation of long- 
and short-term plasma cells during a 
T-dependent or -independent immune 
response, both in spleen and in BM.
The distribution of spleen B cell 
populations can be characterized by 
differential surface expression of CD21, CD23, 
IgM and IgD (Figure R14).  These stainings 
allow us to separate the differentiation 
stages:  the precursor transitional B cells 
(T1 and T2), which further differentiate into 
marginal zone B cells (IgMhiIgDloCD23-Cd21hi) 
or follicular cells (IgMioIgDhiCD23+Cd21int).
The reduction in the total number 
of B lymphocytes observed in the c-mycfl/
fl mice affected both marginal zone (MZ, 
CD23loCD21hi) and follicular B cells (FO, 
CD23hiCD21lo) (Figure R15).  When these 
populations were analyzed by flow cytometry 
in non-immunized, in TNP-KLH and in LPS-
immunized mice, the MZ/follicular cell ratio was 
decreased two-fold in mutant mice compared 
to controls (Figure R15).  Nonetheless, 
hematoxylin/eosin-stained sections showed 
no apparent alterations in the spleen 
structure of c-mycfl/fl mice (Figure R16C).
To determine the distribution of follicular 
Figure R14.  Surface markers to classify B lymphocyte populations in the murine spleen. 
NF (newly formed)/T1(transitional stage 1), T2-FP (transitional stage 2-follicular precursors), FO 
(follicular B cells), T2-MZP (transitional stage 2-MZ B cell precursors), MZ (marginal zone B cells). 
(Based on Pillai et al., 2005)
Results
and marginal zone populations in the 
spleen, we performed immunofluorescence 
in TNP-KLH-immunized c-mycfl/fl and control 
c-mycfl/+ mice.  Consistent with the flow 
cytometry results, staining with MOMA-1, 
which binds metallophilic MZ macrophages 
delimiting the inner ring of the marginal 
zone, indicated almost complete absence 
of c-Myc-deficient B lymphocytes (GFP+) 
in the c-mycfl/fl mouse MZ (Figure R16A). 
Similarly, anti-Cre antibody staining showed 
the absence of Cre-expressing cells in 
the MZ of these mice (Figure R17B).
Based on these data, we conclude that 
total numbers of follicular and MZ B cells are 
reduced in spleens of c-Myc deficient mice, 
which also show a severe reduction in the 
MZ/F ratio before and after antigen stimulation.
4.8 c-Myc-deficient B cells do not 
generate GC
The generation of GC is one of the 
hallmarks of a T cell-dependent immune 
response.  These structures contain rapidly 
proliferating B cells that differentiate into 
plasma and/or memory B cells, in which 
SH and CSR events take place.  To test 
whether c-mycfl/fl mice generated GC after 
immunization with TNP-KLH, we analyzed 
Figure R15.  Follicular and MZ B cell populations in c-Myc-deficient mice.  A) Spleens 
of c-mycfl/fl or control mice were analyzed in preimmune conditiions or after LPS or TNP-KLH 
immunization.  Cells were stained for CD23 and CD21 by flow cytometry to study the MZ and FO 
populations.  B) Absolute cell numbers in whole spleen for populations in (A). n = 6.
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Figure R16. Notable reduction in MZ B cells in c-Myc-deficient mice in MOMA-1 
immunofluorescence.  Spleen cryosections from TNP-KLH-immunized c-mycfl/fl or control mice 
were stained with anti-MOMA-1, -B220 and -GFP antibodies (A) or with anti-MOMA-1 and -Cre 
(B) to identify MZ B cells.  DAPI was used for cell nuclei co-staining.  C) Hematoxylin/eosin (H&E) 
staining of c-mycfl/fl or control mice; n = 5.
Results
surface expression of GL-7 by flow 
cytometry.  The GC B cells can be identified 
by high expression of GL-7 on surface (Han 
et al., 1997).  Spleen cells stained with GL-7 
showed a marked decrease in the population 
of B220+GL-7hiGFP+ germinal center B 
cells (1.3% vs 0.3%) in immunized c-mycfl/
fl mice (Figure R12C and D).  In contrast, 
non-deleted wt B cells (B220+GFP-) from 
the same mouse expressed normal surface 
Figure R17.  c-Myc-deficient B cells do not generate GC after TD stimulation. Spleen 
cryosections of TNP-KLH-immunized c-mycfl/fl or control mice were stained with PNA lectin, 
anti-B220 and -GFP antibodies (A) or with PNA, anti-B220 and -Cre (B) to identify GC B cells. 
DAPI was used to co-stain cell nuclei. C) Number of GC per spleen section; 4-5 sections were 
counted per mouse; n = 5. White bar, c-mycfl/fl mice; black bar, controls.
Results
levels of GL-7 (Figure R12 C and D).  GC 
B cells can be also identified by the binding 
to peanut agglutinin (PNA) (Molin et al., 
1986).  We performed immunofluorescence 
with biotinylated PNA lectin to sduty the 
generation of GC in spleen sections from 
c-Myc deficient or control mice.  c-mycfl/fl mice 
generated GC after immunization (Figure 
R17C); however, these GC contained mostly 
GFP- or Cre- cells (Figure R17 A and B).  We 
concluded that c-Myc-deficient GFP+ cells 
were not responsible for GC generation 
in these mice, and that this protein was 
necessary for GC formation.  These 
structures were thus probably generated 
by wt B cells that escaped Cre-mediated 
c-myc deletion (GFP-) in homozygous mice.
4.9 c-Myc is necessary for the 
maintenance of memory B lymphocytes
As a result of T-dependent B cell 
stimulation, short-term and long-term PC are 
generated.  Memory B cells also arise; they 
have a very long half-life and the capacity 
to generate PC very quickly after a second 
exposure to antigen.  It remains to be 
elucidated whether differentiation to PC and 
memory B cells from mature B cells follow the 
Figure R18.  Lack of antigen-specific memory B cells in c-Myc-deficient mice.  A) TNP-
speciﬁc memory B cells were identiﬁed by flow cytometry in immunized mice, 12 days after a 
second TNP-KLH immunization, by excluding IgM+, IgD+, Gr-1+, F4/80+ cells (MIX negative) and 
staining for TNP-BSA (antigen-speciﬁc) and the indicated additional markers.  B) Absolute numbers 
of memory B cells (Mix-GFP+B220+IgG1+TNP+) from (A) (n = 4), *p<0,05.
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same pathway.  To determine whether c-Myc 
is necessary for memory B cell generation 
or maintenance, we analyzed the memory 
compartment in c-mycfl/fl mice immunized 
with TNP-KLH and challenged with the same 
TNP-KLH dose 28 days later.  Flow cytometry 
analysis showed a severely reduced 
percentage of B220+IgG1+CD38+TNP+GFP+ 
cells, gated into IgM, IgD, Mac-1 and 
F4/80 negative (13.8% vs 11.3%) in the 
spleen of immunized c-mycfl/fl compared 
to control mice, corresponding to antigen-
specific memory B cell that have switched 
to IgG1 (Figure R18 A).  This reduction 
correlates with absolute numbers of TNP-
specific memory B cells in whole spleen 
(Figure R18 B).  These data indicate that 
c-Myc is necessary for the generation 
and/or maintenance of memory B cells.
4.10 Lentiviral infection to rescue plasma 
cell differentiation in c-Myc-deficient 
B cells
Comparison of Blimp-1 downregulation 
in c-Myc-deficient and control B cells after 
anti-CD40 plus IL-4 activation suggested that 
this expression profile was responsible for the 
Figure R19. Transduction of c-Myc-deficient B cells with Blimp-1-expressing lentivirus. 
Sorted B220+GFP+ cells from from c-mycfl/fl or control mice were infected with Blimp1-expressing, 
mock LV vectors or not infected (control), followed by activation with anti-CD40 plus IL-4.  Cells 
were stained on day 3.5 post-activation for the indicated markers. Experiment representative of 
two independen texperiments with three mice (n = 6).
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PC differentiation blockade.  We conjectured 
that normalization of the expression of these 
transcription factor involved in plasma cell 
differentiation might rescue the generation 
of B220loSynd-1+ cells in vitro.  We chose a 
lentiviral vector to overexpress the Blimp-1 
gene (prdm1); a retroviral vector was not 
suitable for infection of c-Myc-deficient B 
lymphocytes, as transduction specificity 
of retroviruses is restricted to proliferating 
cells. We used the EF.CMV.RFP vector 
and specifically the CMV promoter in this 
lentivirus to overexpress the transgenes, 
as CMV yields higher expression levels in 
primary B cells than the EF2alpha promoter 
(Yu et al., 2003).  We replaced the red 
fluorescent protein (RFP) sequence, which 
was toxic to our primary B cells, with an IRES, 
followed by truncated human CD2 (hCD2t). 
The prdm1 coding sequence (Chang et al., 
2000) was then cloned before the IRES, 
under the control of the CMV promoter. 
The transduced B cells were tracked by the 
simultaneous surface expression of hC2Dt 
(identified by flow cytometry analysis) and the 
transgene prdm1, mediated by the bicistronic 
mRNA generated by the IRES sequence.
B220+GFP+ cells from c-mycfl/fl or 
control mice were sorted and infected 
with EF.CMV.Blimp-1-IRES-hCD2t or with 
a control empty vector, EF.CMV.IRES-
hCD2t, at a multiplicity of infection (MOI) 
of 10 viral particles per cell.  Cells were 
activated with anti-CD40 plus IL-4 for 3.5 
days, to allow expression of the transgene 
and differentiation to plasmablasts.  B 
cells were then analyzed by flow cytometry 
for hCD2t surface expression and B220/
Synd-1 expression.  Blimp-1 transduction 
was unable to rescue the B220loSynd-1+ 
population (Figure R19).  The flow cytometry 
profile was similar to that of mock-infected 
cells, although infection slightly altered 
the brightness of some populations.
From these experiments, we 
concluded that Blimp-1 overexpression is 
not sufficient to normalize ASC differentiation 
of c-Myc-deficient B cells in vitro.
Discussion
  5. Discussion
Terminal B cell differentiation is a key 
process for the immunity of an organism. 
It provides the immune system with 
antibody-secreting cells, some of which 
lasting for the whole life of the organism, 
which mediate humoral responses that 
defend against many types of antigens 
and pathogens; it also generates 
memory immunity to these antigens.
In addition to pax5 downregulation, 
antibody-secreting cell differentiation requires 
two main events to proceed, Bcl-6 inhibition, 
which allows Blimp-1 upregulation, and Irf-
4 expression to activate Blimp-1, among 
other targets (Klein et al., 2006; Sciammas 
et al., 2006).  The initiation of two of these 
events is still unknown, since the factors 
that inhibit pax5 expression and activate 
irf4 at this level have not been described.
There are many other questions that 
need to be addressed regarding terminal B 
cell differentiation, including whether short- 
and long-lived plasma cells generation follow 
the same pathway or arise from different 
populations, and which factors determine the 
balance between them. Some studies support 
the idea that both populations are derived 
from the same precursor, whereas others 
argue the hypothesis of two differentiated 
pathways.  The very first events that trigger 
plasma cell initiation, that is, which factors 
drive the exit from the B cell activation 
pathway to become ASC, are still undefined.
It is also not known whether the 
cessation of proliferation, typical of terminally 
differentiated cells, which occurs in terminal 
B cell differentiation and is caused by direct 
inhibition of c-myc by Blimp-1, has an 
additional role in this process.  In an in vitro 
study of the BCL1 mature B lymphoma cell line, 
the authors show that c-myc downregulation 
is necessary but not sufficient to induce 
terminal B lymphocyte differentiation (Lin 
et al., 2000).  Nonetheless, much remains 
to be studied regarding this question.
In this thesis, we analyzed the function 
of the proto-oncogene c-myc in terminal B 
lymphocyte differentiation in vitro and in vivo, 
for which we used our previously reported 
c-mycfl/fl model that allows the specific 
deletion of c-myc in mature B lymphocytes. 
Moreover, it allowed us to isolate or trace 
c-Myc-deficient B lymphocytes in vivo, 
based on GFP expression after Cre-
mediated deletion.  We asked specifically 
whether the contribution of c-Myc to 
terminal B lymphocyte differentiation was 
merely the regulation of cell proliferation 
or if it affected other functions. The data 
presented here show c-Myc as a key 
regulator of terminal B cell differentiation, 
and therefore of the immune response.
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Terminal B lymphocyte differentiation 
can be mimicked in vitro by activation with 
T-independent or -dependent stimuli such 
as LPS or anti-CD40 plus interleukin-4, 
respectively. In both conditions, c-Myc-
deficient B lymphocytes do not generate 
typical plasmablasts (B220loSyndecan-1+). 
c-Myc-deficient B cells appear to initiate 
the differentiation program, but fail to 
complete it.  Gene expression levels of 
pdrm-1 (Blimp-1) are decreased in these 
cells compared to controls.  Pdrm-1-/- B 
cells failed to differentiate to plasma cells 
(B220loSynd-1+), although they initiated 
the differentiation program.  The gene 
expression profile of these cells shows 
some similarities to that of c-Myc-deficient 
B lymphocytes.  These Blimp-1 deficient 
cells induce gene expression of xbp-1, igj 
and are able to secrete low amounts of 
immunoglobulin.   We generated a c-Myc-
deficient cell population that shows a similar 
phenotype to that of pre-plasmablasts, in 
which cells are blocked at a stage at which 
they secrete antibody, but are between the 
pre-plasmablast to plasmablast stages.
The blockade we observed is probably 
due to the low expression levels of blimp-1, 
irf4, or both.  The abnormally high of Bcl-
6 levels observed might also block this 
pathway.  This raises the question as to 
whether c-Myc controls Bcl-6, Blimp-1 or Irf4 
expression.  As an alternative to the Blimp-1 
and Irf4 expression defect, the blockade 
could be attributed to a secondary effect due 
to a general defect in signaling, although 
normal surface expression of CD69 or 
CD25 activation markers on c-Myc-deficient 
B cells argues against this possibility.
Although the generation of Synd-1+ 
cells is blocked in our c-Myc KO model, 
we detect large amounts of IgM.  The 
intracellular FACS, immunoprecipitation and 
ELISpot experiments supported the idea 
that these c-Myc -eficient cells hypersecrete 
IgM.  Several syndromes and mutations 
are associated with hyper-IgM secretion. 
One is the hyper-IgM described in AID KO 
mice (Muramatsu et al., 2000; Kuraoka et 
al., 2009), in which mice show elevated IgM 
in serum due to a CSR defect that impairs 
the switch to isotypes other than IgM; other 
examples are certain CD40 (Lanzi et al., 
2010) and CD40 ligand deficiencies (Heinold 
et al., 2010; Aghamohammadi et al., 2009), 
X-linked hyper-IgM (Lee et al., 2005), multiple 
myeloma, Kawasaki disease in humans, 
caused by abnormally high IL-6 levels, Lyn-
deficient B cell syndrome, and Waldenström 
macroglobulinemia (Davis et al., 2010; 
Kelsoe et al., 2010).  To attempt to explain the 
mechanism underlying this hypersecretion, 
we analyzed expression of UPR pathway-
related genes, chaperones, and other 
transcription factors involved in Ig secretion, 
but found no significant differences between 
c-Myc knockout and control cells.  Thus far, 
we can only attribute the hyper-IgM secretion 
to a defect in CSR caused by deficient 
AID expression, resembling the hyper-IgM 
syndrome reported for AID knockout mice.
We also analyzed the immune response 
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to both TD and TI antigens in our KO model. 
Correlating with the data obtained in vitro, 
these mice showed a notable reduction in 
the plasma cell population in spleen and BM 
compared to control mice, in response to both 
types of stimuli. These results reinforce the 
hypothesis that short- and long-term ASC are 
derived from the same differentiation pathway, 
as c-Myc deletion results in abrogation 
of all Synd-1+ cell populations in vivo.
The generation of GC, whose formation 
is crucial for a competent secondary response 
to TD antigens, was highly compromised in 
our c-Myc KO B cells.  This could be due 
to lack of proliferation or to a still unknown 
role of c-Myc in the formation of these 
structures. This deficiency is remarkable, as 
it points to c-Myc as an additional regulator 
of the TD immune response and CSR.
The large decrease in MZ B cells 
in the c-Myc-deficient mouse spleen is 
also noteworthy.  MZ B cells are a non-
recirculating ‘innate-like’ B cell population, 
as they provide a very effective, rapid TI 
response to blood-borne encapsulated 
bacteria due to their repertoire of Ig 
specificity and strategic position near the 
veins that enter the spleen.  Their proximity 
to the MZ metallophilic macrophages that 
trap pathogens from the circulation optimize 
MZ B cell function as well.  These MZ B 
cells bridge the temporal gap between the 
innate response, which is activated within 
hours, and the TD adaptive response, which 
requires approximately two weeks to peak. 
These cells originate from a transitional T2 
population by several differentiation steps. 
The factors that influence the MZ vs FO 
phenotype decision at this branching point 
in differentiation are still unclear.  Some 
authors propose that MZ arise from those 
B cells whose BCR signaling is weaker 
than those that give rise to FO cells (BCR 
strength or bottleneck hypothesis) (Lopes-
Carvalho et al., 2004; Pillai et al., 2005). 
There are several models in which this B cell 
population is compromised; Btk-/- mice show 
an increased MZ B cell compartment at the 
expense of FO cells (Khan et al., 1995), and 
Lyn-/- (a negative regulator of BCR signaling) 
mice have a deficiency in MZ B cells (Seo 
et al., 2001).  OBF.1 mutant mice also show 
defective MZ B cell development (Samardzic 
et al., 2002).  Nonetheless, we observe no 
differences in the expression of any of these 
molecules.  Remarkably, the Notch2 KO 
mouse shows exactly the same alteration 
in the MZ/FO ratio as that described here. 
Theses authors also reported a decreased 
T1 population; this correlates with the c-Myc 
and Notch2 relationship, in which c-Myc is 
one of the target genes in the Notch pathway. 
Saito et al. (Saito et al., 2003) suggest that 
Notch regulates CD21 expression (Makar et 
al. 2001) or that this gene is necessary to 
push the balance towards the MZ phenotype 
during differentiation.  They propose that 
Notch ligands are expressed in the spleen 
by dendritic cells in the MZ, which trigger 
Notch signaling in MZ B cell precursors.
We here report abrogation of CSR in 
vitro.  In contrast, we observed isotypes 
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other than IgM in the sera of mutant mice. 
We obtained a lower tendency in the 
IgG1, IgE and IgG2b isotypes in serum, 
although not statistically significant.  This 
apparent paradox might be explained by 
the incomplete deletion of c-myc in cmycfl/
fl mice; transplant of c-Myc deficient mature 
B cells into Rag-deficient recipients might 
be very useful to clarify this question.
Alternatively, activation by TD antigens 
generates memory B cells that provide a 
rapid, robust and lasting immune response 
after re-encounter with the antigen. 
Memory B cells can be identified in mice 
as a antigen-specific cells that express 
CD38 on surface (Ridderstad et al., 1998). 
We demonstrated that c-Myc controls 
generation and/or maintenance of memory 
B cells.  Our results suggest that short-
lived plasma cell, long-lived plasma cell and 
memory B cells differentiation pathways 
share some steps in the early stages of 
the process, as c-Myc abrogation resulted 
in the lack of these three populations.
To elucidate the details of the mechanism 
by which c-Myc controls all these processes, 
we considered rescue experiments using 
viral vectors to restore wild type expression 
levels of the altered transcription factors. 
The lack of proliferation by our c-Myc 
deficient B lymphocytes did not permit the 
use of retroviral vectors, as their infective 
capacity is restricted to proliferating cells. 
We thus proposed infection with lentiviral 
vectors bearing potent universal promoters. 
We overexpressed Blimp-1 to attempt to 
restore the normal B220loSynd-1+ plasma 
cell population; the experiments showed 
no effect on the c-Myc KO B lymphocytes 
or on control cells.  We confirmed that 
upregulation of the gene carried by the 
lentivirus was approximately 9- to 10-fold 
compared to endogenous expression, but 
this was insufficient to rescue plasma cell 
differentiation.  Bcl-6 overexpression might 
be preventing correct Blimp-1 function 
in PC generation in spite of Blimp-1 
overexpression, as  previously described 
(Diehl et al., 2008), so this could be the reason 
why we do not rescue PC differentiation by 
lentivirus-medianted Blimp-1 upregulation.
Another possibility is irf4 
overexpression, which we will attempt in 
the near future.  The change in the flow 
cytometry staining profile and the decrease 
in CSR and Ig secretion (not shown) 
following infection nonetheless suggest that 
lentiviral transduction alters activation and/
or differentiation, and the in vitro phenotype 
might not be rescued by this means. 
Another possibility is to breed these mice 
with transgenic mice overexpressing Irf4 
or Blimp-1 in the B cell lineage, although 
the only candidates available are the 
Blimp-1EFGP transgenic, which results in 
lack of function (Kallies et al., 2007), and 
the ICSAT transgenic mouse, in which Irf4 
is overexpressed only in T lymphocytes 
(Saito et al., 1999).  The generation of 
such transgenic mice, overexpressing 
one of the two main transcription factors 
involved in PC differentiation specifically in 
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the B cell lineage, would be a useful tool 
for the study of this process in the future.
In summary, based on our in vitro data it 
is clear that c-Myc is essential for the transition 
pre-plasmablast to plasmablast stage, 
pointing to c-Myc as a crucial transcription 
factor in the context of this Blimp-1/Bcl-
6/Irf4/Pax5 ASC network.  Moreover the 
immunization data demonstrated that c-Myc 
does not only regulate cell proliferation in 
terminal B lymphocyte differentiation.  By a 
number of criteria, we have shown that c-Myc 
affects key functions of this process, including 
antibody secretion, CSR and SH, as well as 
immunological memory and alteration of 
populations that are ‘innate-like’ components 
of the immune response (MZ B cells).
Finally, we propose a model in which 
Figure D1.  Model for c-Myc-dependent control of plasma cell differentiation process 
c-Myc is directly or indirectly regulating 
the expression levels of Irf4, Blimp-1 
and/or Bcl-6, and thus controlling the 
process of terminal B cell differentiation, 
apart from ruling proliferation of B 
lymphocytes.  It is showed in figure D1. 
Conclusions
6. Conclusions
1) c-Myc is necessary for the differentiation of naïve mature B cells into B220loSyndecan-1+ plas-
mablasts in vitro.
2) p27 deﬁciency is not sufﬁcient to rescue defective proliferation in c-Myc knockout B cells.
3) c-Myc deﬁcient B lymphocytes generate fewer antibody secreting cells than control cells in 
vitro.
4) The antibody secreting cells generated from c-mycfl/fl B cells hypersecrete IgM in vitro but do not 
secrete other immunoglobulin isotypes.
5) c-myc deletion causes deregulation in the expression of transcription factors involved in plasma 
cell differentiation: downregulation of irf4 and blimp-1 and upregulation of bcl-6.
6) c-mycfl/fl mice generate nor B220loSyndecan-1+ short-lived plasma cells in spleen neither long-
lived PC in the BM, in response to T-dependent (TNP-KLH) or T-independent (LPS) antigens.
7) c-Myc-deﬁcient B cells do not generate germinal centers following immunization with T-depen-
det antigens.
8) The marginal zone/follicular B cells cell ratio is decreased in c-Myc knockout mice.
9) c-Myc is necessary for the generation and/or maintenance of memory B lymphocytes after 
stimulation with T-dependent antigens.
Resumen en español
  7. Resumen
Introducción
El proto-oncogén c-myc fue identificado 
como el homólogo celular del oncogén del 
virus de la mielocitomatosis aviar v-myc 
(Vennstrom et al., 1982).  La desregulación 
de c-myc está envuelta en70.000 casos 
anuales de muerte por cáncer en Estados 
Unidos (Dang, 1999; Nesbit et al., 1999). 
Por tanto, el esfuerzo para estudiar este 
proto-oncogén ha sido muy significativo en 
los últimos años, con miras terapéuticas.
c-Myc pertenece a la familia de 
factores de trascripción de hélice-bucle-
hélice y cremallera de leucina (bHLH-
LZ), junto con N-Myc, L-Myc, B-Myc 
y s-Myc (Henriksson et al., 1993). 
El gen c-myc está localizado en el 
cromosoma 8 humano y contiene 3 exones. 
En el extremo carboxilo terminal c-Myc 
presenta el motivo bHLH-LZ para formar 
dímeros proteicos con Max, cuya unión es 
necesaria para el reconocimiento de las 
secuencias específicas de ADN, llamadas 
cajas-E (canónicas: 5’-CACGTG-3’, y no 
canónicas: 5’-CANNTG-3’), que se hallan 
en los genes diana.  En la región amino 
terminal contiene 2 cajas Myc altamente 
conservadas (MBI y MBII) para transactivar 
sus genes diana (Dang, 1999; Pelengaris 
et al., 2002).  La región central alberga 
las cajas MBIII y IV y las secuencias de 
localización nuclear NLS1 y NLS2, junto 
con varios sitios de fosforilación (Dang 
et al., 1988; Henriksson et al., 1993).
La proteína nuclear c-Myc se expresa 
de forma ubícua durante la embriogénesis 
y en los tejidos adultos que poseen alta 
capacidad proliferativa.  Sin embargo, es 
casi indetectable en las células quiescentes 
o totalmente diferenciadas.  c-Myc se induce 
rápidamente ante la exposición a estímulos 
mitogénicos (Campisi et al., 1984; Kelly et al., 
1983; Eilers, 1991), aunque su vida media es 
muy corta (20-30 minutos) (Hann et al., 1984). 
La familia de proteínas Mad también 
juega un papel en la red de factores de 
transcripción Myc/Max/Mad, puesto que 
antagonizan el efecto de Myc gracias a 
su capacidad para heterodomerizar con 
Max e inhibir la expresión génica (Hurlin et 
al., 1995).  El balance entre dímeros Myc/
Max y Mad/Max determinará el estado de 
activación de sus genes diana comunes 
y el estado celular (Amati et al., 2001).
c-Myc está implicado en numerosas 
funciones biológicas, siendo las más 
destacables la proliferación, el crecimiento 
celular, la apoptosis y la diferenciación. 
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c-Myc promueve la progresión a lo largo del 
ciclo celular (Mateyak et al., 1997; Eilers 
et al., 1991).  Esto se consigue mediante 
la activación de diferentes quinasas 
dependientes de ciclinas (CDK4, CDK2) 
(Steiner et al., 1995; Bouchard et al., 1999) 
y la represión de inhibidores de ciclo celular, 
como p15, p27 y p21 (Hermeking et al., 
2000; Dang, 1999; Grandori et al., 2000). 
Además, c-Myc activa el metabolismo y 
la síntesis de proteínas, controla tanto el 
crecimiento celular como el tamaño corporal, 
como se demostró en estudios realizados 
en Drosophila melanogaster (Johnston 
et al., 1999), y también en linfocitos B y 
hepatocitos de ratón (de Alborán et al., 
2001; Baena et al., 2005).  En cuanto a la 
apoptosis inducida, se describió que Myc 
acelera la muerte celular en condiciones 
de deprivación de factores de crecimiento 
(Askew et al., 1991; Evan et al., 1992).  Esta 
inducción se produce mediante distinas vías 
de señalización (Fas-Fas ligando, TNF y 
TRAIL), que culminan en la activación de 
la cascada de caspasas y la consiguiente 
degradación celular (Hueber et al., 1997; 
Klefstrom et al., 1994; Lutz et al., 1998).
Por otro lado, c-Myc ha sido identificado 
como un factor regulador de la diferenciación 
a distintos tipos celulares.  Puesto que 
el objetivo de esta tesis es el proceso de 
diferenciación B, vamos a centrarnos en 
este campo.  La expresión de c-Myc en el 
linaje B comienza en la fase pro-B tras la 
estimulación con IL-7 (Morrow et al., 1992). 
También se expresa en la población pre-B 
(Zimmerman et al., 1990).  Esto animó a 
distintos grupos a estudiar el posible papel 
de c-Myc en la diferenciación de linfocitos 
B.  Valiéndose de modelos de ganancia 
de función, como el modelo  murino Eµ-c-
myc (Iritani et al., 1999), se describió un 
papel para este gen en la transición pro/
pre-B hacia células B inmaduras.  También 
se ha estudiado el papel de c-Myc en 
la diferenciación de linfocitos B usando 
modelos de pérdida de función.  Sin embargo, 
la letalidad embionaria en torno a día 10.5 
de gestación causada por eliminación de 
c-myc en línea germinal (Davis et al., 1993) 
obligó a los investigadores a crear modelos 
condicionales de inactivación de c-Myc 
en tejidos adultos, creándose en 2001 el 
modelo c-mycflox en el cual la tecnología Cre/
LoxP permite la eliminación de c-myc en el 
ratón adulto (de Alborán et al., 2001).  Estos 
ratones presentan una proliferación deficiente 
de linfocitos B en respuesta a anti-CD40 
más IL-4, acumulándose en fase G0/G1, y 
mostrando un tamaño similar al de células 
no activadas.  Además, poseen niveles 
anormalmente elevados de p27 y muestran 
resistencia a muerte inducida por la vía de 
Fas (de Alborán et al., 2001).  Por otro lado, 
nuestro laboratorio ha descrito recientemente 
la regulación de la diferenciación temprana 
de linfocitos B por parte de c-Myc a través 
del factor de transcripción EBF1, gracias a 
la unión directa de c-Myc al promotor del 
gen ebf1 (Vallespinós et al. 2011, in press).
Aparte del papel descrito para c-Myc 
en diferenciación temprana de linfocitos B, 
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este factor se expresa a distintos niveles a 
lo largo de todo el proceso de maduración, 
hasta que es inhibido cuando las células B 
maduras se diferencian a células plasmáticas 
(CP).  El objetivo de esta tesis es estudiar 
la función de c-Myc en la diferenciación B 
terminal, puesto que creemos que puede 
estar jugando un papel importante, más 
allá del que juega en proliferación.  No hay 
muchos estudios sobre este tema, pero se 
publicó un trabajo con la línea de linfoma B 
maduro BCL1 in vitro, en el cual se dice que 
la represión de c-myc es necesaria pero no 
suficiente para promover la diferenciación 
plasmacítica (Lin et al., 2000).  Sin embargo, 
este trabajo deja una puerta abierta al 
requerimiento de c-Myc en las primeras fases 
de la diferenciación terminal de linfocitos B. 
Vamos a repasar las distintas fases y 
algunos aspectos importantes del proceso 
de diferenciación de linfocitos B.  La 
diferenciación B termpana es un proceso 
finamente regulado que ocurre en el hígado 
fetal o en la médula ósea adulta, desde 
progenitores linfoides hasta células B 
maduras.  Está ligado al reordenamiento de 
los segmentos V(D)J de las cadenas pesada 
(IgH) y ligera (IgJ) de las inmunoglobulinas 
(Ig).  El avance a lo largo de este proceso 
está acompañado de la expresión de varios 
marcadores de membrana que permiten la 
identificación de distinas subpoblaciones 
(Hardy et al., 2001).  Una vez las células B 
han alcanzado la fase de células B maduras 
migran a los órganos linfoides periféricos, que 
incluyen los nódulos linfáticos, los parches 
de Peyer, las vegetaciones y amígdalas, el 
tejido linfoide asociado a las mucosas y la 
pulpa blanca del bazo.  En estos órganos 
las células B naïve se activan mediante el 
reconocimiento de antígeno y se diferencian 
finalmente a CP y linfocitos B de memoria. 
Las CP con las mediadoras de la inmunidad 
humoral, puesto que secretan grandes 
cantidades de Ig, y las células B de memoria 
permiten una rápida y eficiente respuesta 
ante la re-exposición al antígeno, y pueden 
perdurar durante toda la vida del organismo. 
 Nuestro trabajo se centra en el bazo 
de ratón, que se divide en pulpa roja, 
encargada de eliminar eritrocitos viejos, y 
la blanca, donde hallamos las células del 
sistema inmune.  La pulpa blanca engloba 
los folículos, las zonas T (zona periarteolar 
o PALS) y la zona marginal.  Las células 
que entran al bazo provenientes de la 
médula presentan el fenotipo de membrana 
IgMhiIgD+CD23intCD21int-hi y se llaman 
células B transicionales (T1 y T2).  Éstas 
pueden poblar la zona marginal (MZ), entre 
las pulpas roja y blanca, u organizarse en 
folículos.  Las células B de la zona marginal 
(IgMhiIgDloCd21hiCD21hiCD23lo) se activan 
en respuesta a antígenos T-independientes 
(TI), generando plasmablastos (células con 
capacidad proliferativa y de secretar bajos 
niveles de anticuerpos, con características 
intermedias entre linfocito B y CP) y CP de vida 
corta.  Sin embargo, las células B foliculares 
(IgMloIgDhiCD21loCd23hi) pueden activarse 
mediante antígenos T-dependientes (TD), 
formando centros germinales (CG), que son 
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estructuras especializadas en las cuales 
ocurren ciclos consecutivos de división 
celular.  En ellos también tienen lugar 
los procesos de hipermutación somática 
(CSR) y maduración de la afinidad o 
hipermutación somática (SH), que permiten 
generar anticuerpos de diferentes isotipos 
(distintas región constante y función 
efectora) y con afinidades mayores por el 
antígeno.  En estas estructuras se generan 
CP de vida larga y células B de memoria 
(McHeyzer-Williams et al., 2001; Vinuesa 
et al., 2001; Shapiro-Shelef et al., 2005).
Este proceso de diferenciación B 
terminal está controlado por un programa 
transcripcional altamente regulado, en el cual 
la expresión de los genes  necesarios para la 
diferenciación y la activación de linfocitos B 
y la de los que controlan la diferenciación de 
CP son mutuamente excluyentes.  Blimp-1, 
codificada por el gen prdm1, era considerado 
el principal regulador de la diferenciación 
plasmacítica, ya que su expresión induce la 
diferenciación hacia células secretoras de 
anticuerpos (Turner et al., 1994; Shapiro-
Shelef et al., 2003).  Sin embargo, se 
publicó que en ausencia de Blimp-1 es 
posible generar una población de células 
que secretan bajos niveles Ig aunque son 
Syndecan1- (un proteoglicano que se usa 
como marcador  de CP (Sanderson et al., 
1989)), pero ya expresan genes específicos 
de secreción de Ig como xbp1, flt3 e igj, 
gracias a la inhibición de pax5 (Kallies et al., 
2007).  Blimp-1 reprime directamente c-myc 
(Lin et al., 1997), por lo que las CP dejan de 
proliferar.  La disminución de los niveles de 
Pax5 permite la expresión de  Xbp-1, que es 
otro factor de transcripción esencial para la 
diferenciación a CP, puesto que establece el 
fenotipo secretor de estas células.  Gracias a 
sus funciones relacionadas con la respuesta 
a proteínas mal plegadas (UPR), media la 
expansión del retículo endoplasmático (ER) 
, aumento del tamaño celular, síntesis de Ig y 
aumento de la función mitocondrial (Reimold 
et al., 2001).  Irf4 también participa en 
este proceso de diferenciación, realizando 
funciones no solapantes con Blimp-1, y su 
eliminación inhibe la generación de CP. 
Además, juega un papel en CSR a través 
de la activación directa de AID (Klein et 
al., 2996; Sciammas et al., 2006).  Otro 
componente esencial de esta vía es Bcl-6, 
cuya expresión es máxima en los CG, debido 
a su función en el mantenimiento de estas 
estructuras (Cattoretti et al., 1995).  Bcl-6 
inhibe Blimp-1, por lo que debe ser reprimido 
para poder avanzar a lo largo del proceso de 
diferenciación hacia PC (Shaffer et al., 2000). 
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Objetivos
Todo esto, nos hizo plantearnos cuál es el papel de c-Myc en la diferenciación terminal 
de linfocitos B, y proponernos los siguientes objetivos:
Caracterizar el papel de c-Myc en la diferenciación terminal de linfocitos B 1) 
mediante un modelo murino de pérdida de función: generación de células plasmátucas y 
secreción de inmunoglobulinas in vitro.
Caracterizar la respuesta inmune en ratones deﬁcientes en c-Myc-deﬁcient tras 2) 
la inmunización con antígenos T-dependientes y T-independientes.
Analizar los niveles de expresión génica de los principales factores de 3) 
transcripción implicados en la diferenciación terminal de linfocitos B, en ausencia de 
c-Myc.
Rescatar el fenotipo normal de diferenciación mediante ensayos de ganancia 4) 
de función sobre-expresando potenciales genes diana de c-Myc. 
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Resultados
Modelo murino para el estudio de 
la diferenciación B: generación de los 
ratones c-myc fl/fl;cd19cre /+;rosa26efgp/egfp
En esta tesis hemos utilizado el 
modelo condicional de inactivación de 
c-myc en ratón publicado anteriormente 
(de Alboran et al., 2001).  En este modelo 
los exones codificantes 2 y 3 de c-myc 
están flanqueados por secuencias loxP, 
y la expresión específica en linaje B de la 
Cre recombinasa bajo el promotor de cd19 
media su eliminación.  Cruzamos esta cepa 
c-mycfl/f;lcd19cre/+ con ratones que expresan 
la proteína verde fluorescente (EGFP) para 
poder identificar las células en las cuales 
la eliminación de c-myc se ha producido. 
Mediante cruces sucesivos obtuvimos ratones 
homocigotos c-mycfl/fly controles c-mycfl/+.
c-Myc es necesario para 
la diferenciación hacia células 
B220loSyndecan-1+ in vitro
Aislamos células B220+GFP+ del bazo 
de ratones c-mycfl/fl o controles y estudiamos 
la generación de células plasmáticas in 
vitro mediante la activación con anti-CD40 
más IL-4 o LPS.  Observamos que las 
células B deficientes en c-Myc no generan 
células B220loSyndecan-1+ en respuesta 
a ambos antígenos.  Cuando analizamos 
los niveles de expresión en membrana 
del marcador de activación CD69 no 
encontramos diferencias, lo que nos indica 
que este bloqueo no se debe a  un defecto 
en la activación en respuesta a estímulo.
Las células B deficientes en 
c-Myc presentan una disminución 
dramática de la proliferación in vitro
Analizamos la capacidad de proliferar 
de nuestras células B deficientes en c-Myc. 
Por un lado, el tamaño de los blastos formado 
a día 4 de activación con anti-CD40 más IL-4 
era mucho menor que los blastos de células 
control y, por otro lado, el número de células 
recuperada era también inferior.  Además 
realizamos experimentos con yoduro de 
propidio mediante citometría de flujo, y 
observamos que la proliferación de linfocitos 
B deficientes en c-Myc está severamente 
impedida tanto en respuesta a anti-CD40 más 
IL-4 como a LPS, acorde con lo previamente 
publicado  (de Alboran et al., 2001).
La eliminación de p27 
no rescata la proliferación en 
células B deficientes en c-Myc
Según lo publicado en (de Alboran 
et al., 2001), sabemos que la molécula 
inhibidora de ciclo celular p27kip se 
haya sobre-expresada en los linfocitos B 
deficientes en c-Myc.  Por tanto, tratamos 
de normalizar la proliferación en estas 
células mediante la eliminación de p27. 
Para ello cruzamos los ratones c-mycfl/fl y 
c-mycfl/+;cd19cre/+;rosa26gfp/gfp con ratones p27 
“knockout” (p27KO) (Fero et al., 1996).  Sin 
embargo, cuando analizamos el ciclo celular 
en estos ratones, no observamos diferencias 
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respecto a los KO simples c-mycfl/fl.
Los linfocitos B deficientes en 
c-Myc son capaces de generar células 
secretoras de anticuerpos (ASC)
La ausencia de plasmablastos con el 
típico fenotipo de membrana B220lo/-Synd-1+ 
no indica ausencia de células secretoras 
en nuestros cultivos c-Myc KO.  Por tanto, 
analizamos la generación de Ig secretada 
en cultivo mediante ELISA, y la generación 
de células secretoras de anticuerpos 
mediante ensayo de  ELISpot.  Detectamos 
concentraciones similares de IgM, mediante 
ELISA, en los sobrenadantes de células 
KO y control en las activaciones con anti-
CD40 más IL-4.  Por otro lado, los ensayos 
de ELISpot indicaron que los linfocitos 
B deficientes en c-Myc son capaces de 
generar células secretoras de anticuerpos, 
aunque el número total generado in vitro 
era 6 veces menor que en cultivos control. 
Por tanto, dedujimos para que un número 
mucho menor de células secretoras diera 
lugar a un nivel de IgM soluble similar, estas 
células debían empezar a secretar antes que 
las células control, o bien secretar mayores 
cantidades de Ig por célula.  Los estudios de 
cinética de secreción no mostraron ninguna 
diferencia; sin embargo, la medición del área 
de los “spots” de IgM secretada en ELISpot, 
junto con ensayos de inmunoprecipitacion 
de la IgM total en sobrenadantes y la tinción 
de IgM intracelular, demostraron que las 
células B deficientes en c-Myc son capaces 
de hiper-secretar IgM.  En cambio, cuando 
analizamos otros isotipos como IgG1 e IgE, 
generados también en las activaciones 
con anti-CD40 más IL-4, no encontramos 
niveles detectables, indicando que c-Myc es 
necesario para realizar el proceso de CSR.
Expresión génica 
de células secretoras de 
anticuerpos deficientes en c-Myc
Analizamos los niveles de expresión 
de diferentes factores de transcripción 
implicados en la diferenciación de CP 
mediante qPCR.  Extrajimos el RNA 
de células B220+Syndecan-1-GFP+ y/o 
B220loSyndecan-1+GFP+ de ratones c-mycfl/
fl y c-mycfl/+ después de estimularlas in vitro 
con anti-CD40 más IL-4 durante 1 o 3 días. 
La población B220loSyndecan-1+GFP+ no se 
genera todavía a día 1 ni en cultivos mycfl/fl, 
ni en c-mycfl/+; esta población fue purificada 
en las muestras de día 3 de cultivos control, 
ya que las células B deficientes en c-Myc 
no la generaron.  Observamos varios 
cambios significativos en genes clave para 
este proceso: Irf4 y Blimp-1 se encuentran 
4 y 3 veces disminuídos respectivamente, 
comparados con células control.  Bcl-6 se 
haya sobre-expresado, y Xbp-1 no presenta 
cambios significativos.  Estos cambios 
permiten explicar el bloqueo observado en 
la diferenciación de plasmablastos in vitro. 
Además, los niveles normales de Xbp-1 son 
compatibles con la capacidad de secretar Ig 
que presentan nuestras células.  Por otro 
lado, aunque analizamos bastantes genes 
implicados en secreción y en la ruta de UPR, no 
observamos ningún cambio destacable que 
pudiera explicar la super-secreción de IgM. 
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Respuesta inmune impedida en 
ratones c-mycfl/fly ausencia de centros 
germinales deficientes en c-Myc
Estudiamos la respuesta inmune en 
ratones deficientes en c-Myc y controles tras 
la inmunización con antígenos TD (TNP-
KLH) y TI (LPS).  En respuesta a ambos 
estímulos, observamos un gran defecto 
en la generación de células plasmáticas 
B220loSyndecan-1+GFP+, tanto las de vida 
corta que se generan en bazo, como de las 
de vida larga, que migran a la médula ósea. 
 Además, tras la inmunización 
con TNP-KLH observamos una falta de 
generación de células B de centro germinal 
(GL-7hi) por citometría de flujo, y una 
ausencia de centros germinales generados 
a partir de linfocitos B deficientes en c-Myc 
mediante técnicas de inmunohistoquímica. 
Adicionalmente, nos llamó la atención la 
alteración de la proporción de células B 
de zona marginal respecto a las células B 
foliculares, disminuyendo dráscticamente 
en los ratontes homocigotos.  Esto lo 
demostramos tanto por citometría de flujo 
mediante los marcadores CD23 y CD21, 
como por métodos de inmunohistoquímica. 
 Por último, el análisis de los niveles 
de distintos isotipos de Ig en suero tras 
la inmunización con TNP-KLH no reveló 
cambios significativos, pero sí sugieren 
una tendencia a la hipersecreción de IgM 
y disminución del resto de isotipos.  La 
existencia de un porcentaje de células en 
las cuales no se elimina c-Myc dentro de los 
ratones homocigotos, debido a la incompleta 
acción de la recombinasa Cre, hace que nos 
sea imposible en este modelo determinar 
los niveles reales de Ig liberada al suero 
únicamente por las células c-Myc deficientes.
c-Myc es necesario 
para el mantenimiento de 
los linfocitos B de memoria
Estudiamos la generación de linfocitos 
B de memoria en ratones deficientes 
en c-Myc tras la inmunización con TNP-
KLH.  Los análisis de citometría de flujo 
tras re-estimulación con este antígeno 
mostraron una severa reducción de las 
células B220+IgG1+CD38+TNP+GFP+, 
que son linfocitos B de memoria 
específicos de antígeno. 
Infección lentiviral de linfocitos B 
deficientes en c-Myc para rescatar la 
diferenciación hacia células plasmáticas 
Puesto que los niveles de Blimp-1 
se hayan disminuidos significativamente 
en los linfocitos B deficientes en c-Myc, 
tratamos de restablecer los niveles de este 
factor de trancripción tan importante para la 
diferenciación de células plasmáticas.  Para 
ello infectamos las células B con un vector 
lentiviral con el fin de sobre-expresar Blimp-1. 
No podemos utilizar vectores retrovirales en 
nuestro caso, puesto que infectan células 
en división. Utilizando el vector EF.CMV.
Blimp-1-IRES-hCD2t o el vector control 
EF.CMV.IRES-hCD2t, infectamos células 
B220+GFP+ de ratones c-mycfl/fl  o control 
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y las activamos posteriormente con anti-
CD40 más IL-4.  Cuando analizamos por 
citometría de flujo la diferenciación hacia 
células B220loSynd-1+, no observamos 
ningún efecto del vector que sobre-expresa 
Blimp-1 respecto del vacío.  Sin embargo, 
la mera infección alteró bastante tanto la 
diferenciación de las células in vitro como 
el brillo de los marcadores analizados 
en citometría, e incluso la secreción de 
inmunoglobulinas.  También nos planteamos 
infectar las células con un vector que 
sobre-expresase Irf4, pero el hecho de 
que la infección lentiviral altere tanto la 
diferenciación a células plasmáticas, nos 
hace dudar que mediante este procedimiento 
experimental se pueda rescatar el fenotipo 
normal de las células B deficientes en 
c-Myc.  El uso de ratones transgénicos 
que sobre-expresen Blimp-1 o Irf4 serían 
de gran utilidad para este tipo de estudios.
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Conclusiones
1) c-Myc es necesario para la diferenciación hacia plasmablastos B220loSyndecan-1+ in vit-
ro.
2) La deﬁciencia en p27 no es suﬁciente para rescatar la proliferación en células deciﬁcientes 
en c-Myc. 
3) Los linfocitos B deﬁcientes en c-Myc generan menos células secretoras de anticuerpos que 
los linfocitos control. 
4) Las células secretoras de Ig generadas a partir de células B c-mycfl/fl hiper-secretan IgM in 
vitro, pero no secretan otros isotipos de Inmunoglobulinas. 
5) La eliminación de c-Myc causa la desregulación de la expresión de varios factores de tran-
scripción implicados en diferenciación hacia células plasmáticas: disminución de la expresión 
irf4 y blimp-1, sobre-expresión de bcl-6.
6) c-mycfl/fl no genera células plasmáticas de vida corta B220loSyndecan-1+ en el bazo ni de 
vida larga en la médula ósea, en respuesta a antígenos T-dependientes (TNP-KLH) o T-
independientes (LPS).
7) Las células B deﬁcientes en c-Myc no generan centros germinales tras inmunización T-
depeniente.
8) El ratio entre linfocitos B de zona marginal y foliculares está severamente disminuído en 
ratones deﬁcientes en c-Myc.
9) c-Myc es necesario para la generación y/o mantenimiento de linfocitos B de memoria tras 
la estimulación T-dependiente. 
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and regulates LinSca-1þc-Kit cell generation through p21
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Objective. The c-Myc protein is a member of the basic region/helix-loop-helix/leucine zipper
(bHLHZip) transcription factor family, which is implicated in regulation of proliferation, dif-
ferentiation, and apoptosis in multiple cell types. The aim of this study was to characterize the
role of the proto-oncogene c-myc in hematopoietic stem cells (HSC) during postnatal
development.
Material and Methods. We have generated a conditional mouse model that allows us to inac-
tivate c-myc in bone marrow (BM) in an inducible fashion.
Results. We show that conditional inactivation of c-Myc in BM severely impairs HSC differ-
entiation, leading to a striking decrease in the number of lymphoid and myeloid cells. c-Myc
deletion in BM causes substantial accumulation of a LinLSca-1+c-KitL cell population ex-
pressing high levels of the cell-cycle inhibitor p21, whose origin and function are otherwise
poorly characterized. In vivo inactivation of p21 and c-Myc normalizes LinLSca-1+c-KitL
cell numbers and restores normal proliferation. The potential origin and function of these
cells are discussed.
Conclusions. c-Myc plays a role in HSC maintenance and differentiation and might be regu-
lating generation of LinLSca-1+c-KitL through the cell-cycle regulator p21.  2007 ISEH -
Society for Hematology and Stem Cells. Published by Elsevier Inc.Given the appropriate environment, hematopoietic stem
cells (HSC) are able to perpetuate themselves by self-
renewal and to differentiate into all blood cell types. Under
normal physiological conditions, the number of HSC is
kept constant. HSC must, therefore, maintain the balance
between differentiation and self-renewal to provide an input
of differentiated cells [1,2]. Numerous reports have focused
on the understanding of the molecular mechanisms that
govern HSC differentiation and self-renewal, with the aim
to improve the potential clinical applications of these cells.
HSC are included in a bone marrow (BM) population de-
fined by surface expression of Sca-1 and c-Kit in the line-
age-negative (Lin) fraction (LinSca-1þc-Kitþ, LSK
cells). LSK cells can be further characterized based on sur-
face expression of different markers in cells with long-term
Dr. Baena is currently at Children’s Hospital, Division of Hematology/
Oncology, Boston, MA.
Offprint requests to: Ignacio Moreno de Albora´n, Ph.D. Universidad
Autonoma de Madrid, Centro Nacional de Biotecnologia/CSIC, Depart-
ment of Immunology and Oncology, Darwin 3, Madrid E-28049, Spain;
E-mail: imoreno@cnb.uam.es0301-472X/07 $–see front matter. Copyright  2007 ISEH - Society for Hema
doi: 10.1016/j.exphem.2007.05.015multilineage reconstitution potential and self-renewal activ-
ity and short-term with limited self-renewal potential in
irradiated mice [3].
Several molecular pathways have been implicated in the
regulation of HSC self-renewal and differentiation. Hoxb4,
a member of the homeobox gene transcription factor fam-
ily, is expressed in HSC and promotes their in vivo and in
vitro expansion [4,5]. Moreover, ectopic hoxb4 expression
confers multilineage engraftment potential to embryonic
stem cells and yolk sac hematopoietic precursors. Wnt pro-
teins have been shown to play an important role in verte-
brate and invertebrate development. In HSC, activation of
the Wnt signaling pathway and stabilization of b-catenin
promote self-renewal in vitro and enhance the capacity of
hematopoietic precursors to reconstitute lethally irradiated
mice [6]. Another gene that has been shown to play a
prominent role in HSC homeostasis is Bmi-1. This gene is
a member of the polycomb family of genes involved in
lymphocyte development, senescence, and neurological
development. Inactivation of bmi-1 gene in mice leads to
progressive loss of all hematopoietic lineages due to a defect
inHSCself-renewal capacity [7,8].Othermolecular pathwaystology and Stem Cells. Published by Elsevier Inc.
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